var title_f19_22_19808="Positive SAECG following myocardial infarction";
var content_f19_22_19808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Late potentials on the signal-averaged ECG suggesting possible substrate for reentrant ventricular arrhythmias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Signal-averaged electrocardiogram (SAECG) showing a QRS complex after a first and second myocardial infarction (MI) in the same patient. Left panel: After a first MI, no late potentials are present on the SAECG. Right panel: After a second MI, late potentials are seen as low amplitude signals at the end of the QRS complex (arrow). The filtered QRS duration is increased to &gt;120 msec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19808=[""].join("\n");
var outline_f19_22_19808=null;
var title_f19_22_19809="Calculator: Creatinine clearance estimate by Cockcroft-Gault equation (SI units)";
var content_f19_22_19809=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CreatinineCl_CG_SI_form\" name=\"CreatinineCl_CG_SI_form\" onkeydown=\"clrResults();\" onkeyup=\"CreatinineCl_CG_SI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Creatinine clearance estimate by Cockcroft-Gault equation (SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          CreatClear = (Sex * (140 - Age) * Weight * 1.23) / SerumCreat",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sex",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Sex_radio\" onclick=\"CreatinineCl_CG_SI_fx();\" type=\"radio\" value=\"Male|1\"/>",
"              Male (1)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Sex_radio\" onclick=\"CreatinineCl_CG_SI_fx();\" type=\"radio\" value=\"Female|0.85\"/>",
"              Female (0.85)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"CreatinineCl_CG_SI_fx(); minMaxCheck();\" onchange=\"CreatinineCl_CG_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               years",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Creat",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Creat_param\" onblur=\"CreatinineCl_CG_SI_fx(); minMaxCheck();\" onchange=\"CreatinineCl_CG_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               mcmol/L",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"CreatinineCl_CG_SI_fx(); minMaxCheck();\" onchange=\"CreatinineCl_CG_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               kgs",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Creat Clear",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Creat_Clear_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                mL/min",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"CreatinineCl_CG_SI_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      You can estimate the creatinine clearance (",
"      <b>",
"       Creat Clear",
"      </b>",
"      ) from the formula if the serum",
"creatinine concentration is stable. The",
"      <b>",
"       Weight",
"      </b>",
"      is the estimated lean body weight.",
"(See UpToDate topic reviews that discuss calculation of the creatinine clearance, for a review",
"of the creatinine clearance as an estimate of the true glomerular filtration rate).",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     Equation parameters such as",
"     <b>",
"      Sex",
"     </b>",
"     have two or more discrete values that may be used in the calculation. The numbers in the parentheses, e.g.  (1), represent the values that will be used.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.",
"        <i>",
"         Nephron",
"        </i>",
"        . 1976;16(1):31-41.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19809=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function CreatinineCl_CG_SI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.CreatinineCl_CG_SI_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 0.85; }",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"Age = param_value;",
"if (Serum_Creat_param.value.indexOf(',') >= 0){ Serum_Creat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Creat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"Serum_Creat = param_value;",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"Weight = param_value;",
"dp = decpts.options[decpts.selectedIndex].text;",
"Creat_Clear =  (Sex * (140 - Age) * Weight * 1.23) / Serum_Creat;",
"",
"if (doCalc) Creat_Clear_param.value = fixDP(Creat_Clear, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CreatinineCl_CG_SI_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 years.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 120) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 120 years.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CreatinineCl_CG_SI_form){",
"",
"Creat_Clear_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f19_22_19809=null;
var title_f19_22_19810="Prenatal ultrasound of SUA in hypercoiled cord";
var content_f19_22_19810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of a single umbilical artery in a hypercoiled umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conventional two-dimensional ultrasound shows a potential pitfall in the diagnosis of single umbilical artery. The diagnosis can be easily missed in hypercoiled umbilical cords.",
"    <div class=\"footnotes\">",
"     v: vein; a: single umbilical artery.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19810=[""].join("\n");
var outline_f19_22_19810=null;
var title_f19_22_19811="Chalazion eyelid PI";
var content_f19_22_19811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Chalazion in the eyelid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chalazion is a firm, painless bump that can form in the upper eyelid (A) or the lower eyelid (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19811=[""].join("\n");
var outline_f19_22_19811=null;
var title_f19_22_19812="Metaproterenol: Drug information";
var content_f19_22_19812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metaproterenol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/29/34260?source=see_link\">",
"    see \"Metaproterenol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/9/1172?source=see_link\">",
"    see \"Metaproterenol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3149994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Orciprenaline&reg;;",
"     </li>",
"     <li>",
"      ratio-Orciprenaline&reg;;",
"     </li>",
"     <li>",
"      Tanta-Orciprenaline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Bronchoconstriction:",
"     </b>",
"     Oral: 20 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/9/1172?source=see_link\">",
"      see \"Metaproterenol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Bronchoconstriction:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;6 years (limited experience): 1.3-2.6 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-9 years (or &lt;27 kg): 10 mg/dose 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;9 years (or &ge;27 kg); Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as sulfate: 10 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F193715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer orally without regards to food. May administer with food if GI upset occurs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchodilator in reversible airway obstruction due to asthma or COPD",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metaproterenol may be confused with metipranolol, metoprolol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alupent may be confused with Atrovent&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (6% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness (5% to 20%), headache (1% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (2% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%), insomnia (2%), fatigue (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1% to 4%), diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Chest pain, diaphoresis, edema, facial/finger edema, hives, hypertension, laryngeal changes, spasms, syncope, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metaproterenol or any component of the formulation; pre-existing cardiac arrhythmias associated with tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: Metaproterenol (a less selective beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist) is not recommended in the management of asthma due to potential for excessive cardiac stimulation. Oral systemic agents (eg, tablets, syrup) should be avoided due to increased risk of adverse effects (eg, excessive cardiac stimulation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic obstructive lung disease (COPD): Appropriate use: Inhaled bronchodilators are preferred therapy for COPD exacerbations; oral systemic agents (eg, tablets, syrup) should be avoided due to increased risk of adverse effects (eg, excessive cardiac stimulation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may elevate intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in hyperthyroidism; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and embryotoxic effects have been observed in some animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F193738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Metaproterenol Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (473 mL): $31.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Metaproterenol Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $99.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $139.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lung sounds, heart rate, and blood pressure; FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; CNS stimulation; serum glucose, serum potassium (in selected patients)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alupent (AE, AT, BH, CY, EG, GB, GR, ID, IE, IL, IN, IQ, IR, IT, JO, KW, LB, LY, NL, OM, PE, QA, RU, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nonasma (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors which increases the conversion of adenosine triphosphate (ATP) to 3&rsquo;-5&rsquo;-cyclic adenosine monophosphate (cAMP), resulting in bronchial smooth muscle relaxation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Bronchodilation: Oral: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Oral: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~2-6 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilman MJ, Meyer L, Carter J, et al, &ldquo;Comparison of Aerosolized Glycopyrrolate and Metaproterenol in Acute Asthma,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1990, 98(5):1095-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19812/abstract-text/2225951/pubmed\" id=\"2225951\" target=\"_blank\">",
"        2225951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jerrard DA, Olshaker J, Welebob E, et al, &ldquo;Efficacy and Safety of a Rapid-Sequence Metaproterenol Protocol in the Treatment of Acute Adult Asthma,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(4):392-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19812/abstract-text/7605520/pubmed\" id=\"7605520\" target=\"_blank\">",
"        7605520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9619 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19812=[""].join("\n");
var outline_f19_22_19812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3149994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193748\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193733\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193743\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193734\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193711\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193695\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193715\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193714\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193756\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193746\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193699\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299679\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193704\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193707\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193722\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193738\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323378\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193709\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038675\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193698\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193717\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9619|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/29/34260?source=related_link\">",
"      Metaproterenol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/9/1172?source=related_link\">",
"      Metaproterenol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_22_19813="Cladribine: Patient drug information";
var content_f19_22_19813=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cladribine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     see \"Cladribine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/10/11430?source=see_link\">",
"     see \"Cladribine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700695",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney problems in some patients. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3411937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad nerve problems that may lead to not being able to move a part of the body (paralysis). Call your doctor if you have numbness, tingling, or weakness in your arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691948",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macroglobulinemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4014964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Langerhans cell histiocytosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cladribine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11331 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19813=[""].join("\n");
var outline_f19_22_19813=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024160\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024162\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024161\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024166\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024167\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024169\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024164\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024171\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=related_link\">",
"      Cladribine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/10/11430?source=related_link\">",
"      Cladribine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_22_19814="Invasive UC glandular diff";
var content_f19_22_19814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Invasive urothelial carcinoma with glandular differentiation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A, The presence of true glandular spaces within the urothelial component characterizes the glandular differentiation in urothelial carcinoma (20x). B, Apical cytoplasm and more basally situated nuclei of true glandular differentiation are noted at high power (40x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19814=[""].join("\n");
var outline_f19_22_19814=null;
var title_f19_22_19815="Cladribine: Drug information";
var content_f19_22_19815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cladribine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/22/19813?source=see_link\">",
"    see \"Cladribine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/10/11430?source=see_link\">",
"    see \"Cladribine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Purine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hairy cell leukemia:",
"     </b>",
"     I.V.: 0.09 mg/kg/day continuous infusion for 7 days for 1 cycle",
"     <b>",
"      or",
"     </b>",
"     (unlabeled dosing) 0.1 mg/kg/day continuous infusion for 7 days for 1 cycle (Goodman, 2003; Saven, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute myeloid leukemia, induction (unlabeled use):",
"     </b>",
"     I.V.: CLAG or CLAG-M regimen: 5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours for 5 days; a second induction may be administered if needed (Robak, 2000; Wierzbowska, 2008; Wrzesie��-Ku��, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic lymphocytic leukemia (unlabeled use):",
"     </b>",
"     I.V.: 0.1 mg/kg/day continuous infusion for 7 days every 4-5 weeks (Saven, 1995)",
"     <b>",
"      or",
"     </b>",
"     0.14 mg/kg/day over 2 hours for 5 days every 28 days for 3-6 cycles (Byrd, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mantle cell lymphoma (unlabeled use):",
"     </b>",
"     I.V.: 5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours for 5 days every 4 weeks for 2-6 cycles (Inwards, 2008; Rummel, 1999)",
"     <b>",
"      or",
"     </b>",
"     5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours for 5 days every 4 weeks for 2-6 cycles  (in combination with rituximab) (Inwards, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Waldenstr&ouml;m&rsquo;s macroglobulinemia (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.1 mg/kg/day continuous infusion for 7 days every 4 weeks for 2 cycles (Dimopoulos, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 0.1 mg/kg/day for 5 consecutive days every month for 4 cycles (in combination with rituximab) (Laszlo, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F152303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/10/11430?source=see_link\">",
"      see \"Cladribine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute myeloid leukemia (unlabeled use):",
"     </b>",
"     I.V.: 8.9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days for 1 or 2 courses (Krance, 2001)",
"     <b>",
"      or",
"     </b>",
"     9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 30 minutes for 5 days for 1 course (in combination with cytarabine) (Crews, 2002; Rubnitz, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Langerhans cell histiocytosis, refractory (unlabeled use):",
"     </b>",
"     I.V.: 5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours for 5 days every 21 days for up to 6 cycles (Weitzman, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5527019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (due to inadequate data); use with caution. The following adjustments have been used (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 30% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 30% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5527020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (due to inadequate data); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer as a continuous infusion. May also be administered over 30 minutes or over 2 hours (unlabeled administration rates) depending on indication and/or protocol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ (unlabeled route): May also be administered SubQ (Laszlo, 2010)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F152325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, chlorpromazine, cimetidine, cisplatin, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, diphenhydramine, dobutamine, dopamine, doxorubicin HCl, droperidol, enalaprilat, etoposide, famotidine, furosemide, gallium nitrate, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, idarubicin, leucovorin calcium, lorazepam, mannitol, meperidine, mesna, methylprednisolone sodium succinate, metoclopramide, mitoxantrone, morphine, nalbuphine, ondansetron, paclitaxel, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, teniposide, vincristine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of active hairy cell leukemia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F152316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphomas (mantle cell), Waldenstr&ouml;m&rsquo;s macroglobulinemia, refractory Langerhans cell histiocytosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cladribine may be confused with clevidipine, clofarabine, cytarabine, fludarabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Leustatin&reg; may be confused with lovastatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (33% to 69%; &ge;100&deg;F: 67%; &ge;104&deg;F: 11%), fatigue (11% to 45%), headache (7% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (10% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (22% to 28%), appetite decreased (8% to 17%), vomiting (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (grade 4: 70%; recovery: by week 5); anemia (1% to 37%; recovery: by week 8); myelosuppression (34%; prolonged), neutropenic fever (8% to 47%; severe: 32%), thrombocytopenia (grade 4: 12%; recovery: by day 12)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (9% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Abnormal breath sounds (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (month 1: 28% [serious: 6%]; month 2: 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (2% to 6%), tachycardia (2% to 6%), thrombosis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (2% to 9%), dizziness (6% to 9%), insomnia (3% to 7%), malaise (5% to 7%), pain (6%), anxiety (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Purpura (10%), petechiae (2% to 8%), pruritus (2% to 6%), erythema (6%), hyperhidrosis (3%), bruising (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (7% to 10%), constipation (4% to 9%), abdominal pain (4% to 6%), flatulence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (6% to 9%), myalgia (6% to 7%), arthralgia (3% to 5%), muscle weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (7% to 10%), abnormal chest sounds (9%), dyspnea (5% to 7%), epistaxis (5%), rales (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aplastic anemia, bacteremia, CD4 lymphocytopenia (nadir: 4-6 months), cellulitis, consciousness decreased, conjunctivitis, hemolytic anemia, hypereosinophilia, hypersensitivity, myelodysplastic syndrome, opportunistic infections (cytomegalovirus, fungal infections, herpes virus infections, listeriosis, Pneumocystis jirovecii), pancytopenia (prolonged), paraparesis, pneumonia, polyneuropathy (with high doses), progressive multifocal leukoencephalopathy (PML), pulmonary interstitial infiltrates, quadriparesis (reported at high doses); renal dysfunction (with high doses), renal failure, septic shock, Stevens-Johnson syndrome, stroke, toxic epidermal necrolysis, tuberculosis reactivation, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cladribine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Dose-dependent myelosuppression (neutropenia, anemia, and thrombocytopenia) is common and generally reversible.",
"     </b>",
"     Use with caution in patients with pre-existing hematologic or immunologic abnormalities. Monitor blood counts, especially during the first 4-8 weeks after treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fever: Treatment is associated with fever (&gt;100&deg;F), with or without neutropenia, observed more commonly in the first month.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Infections (bacterial, viral, and fungal) were reported more commonly in the first month after treatment (generally mild or moderate in severity, although serious infections including sepsis have been reported); the incidence is reduced in the second month. Due to neutropenia and T-cell depletion, risk versus benefit of treatment should be evaluated in patients with active infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Serious, dose-related neurologic toxicity (including irreversible paraparesis and quadriparesis) has been reported with continuous infusions of higher doses (4-9 times the FDA-approved dose); may also occur at approved doses (rare).",
"     </b>",
"     Neurotoxicity may be delayed and may present as progressive, irreversible weakness; diagnostics with electromyography and nerve conduction studies were consistent with demyelinating disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acute nephrotoxicity (eg, acidosis, anuria, increased serum creatinine), possibly requiring dialysis, has been reported with high doses (4-9 times the FDA-approved dose), particularly when administered with other nephrotoxic agents.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: With high tumor burden, tumor lysis syndrome and subsequent hyperuricemia may occur (rare); consider allopurinol and hydrate accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Diluted product may contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Administration of live vaccines is not recommended during treatment with cladribine (may increase the risk of infection due to immunosuppression).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F152281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3016299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects and fetal mortality were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of reproductive potential should use highly effective contraception during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3016301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue cladribine or to discontinue breast-feeding should take into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cladribine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (10 mL): $420.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F152261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     CBC with differential (particularly during the first 4-8 weeks post-treatment), renal and hepatic function; bone marrow biopsy (after CBC has normalized, to confirm treatment response); monitor for fever; monitor for signs/symptoms of neurotoxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ai Bo Ding (CL);",
"     </li>",
"     <li>",
"      Biodribin (PL);",
"     </li>",
"     <li>",
"      Cladrim (IN);",
"     </li>",
"     <li>",
"      Intocel (AR);",
"     </li>",
"     <li>",
"      Leustat (AR, GB, IE, UY);",
"     </li>",
"     <li>",
"      Leustatin (AT, AU, BE, BG, BR, CH, CR, DO, ES, FI, GR, GT, HK, HN, IT, KP, LU, NI, NL, NO, NZ, PA, PH, PT, SE, SG, SV, TW, VE);",
"     </li>",
"     <li>",
"      Leustatine (FR);",
"     </li>",
"     <li>",
"      Litak (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IL, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR, TW);",
"     </li>",
"     <li>",
"      Movectro (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A purine nucleoside analogue; prodrug which is activated via phosphorylation by deoxycytidine kinase to a 5'-triphosphate derivative (2-CaAMP). This active form incorporates into DNA to result in the breakage of DNA strand and shutdown of DNA synthesis and repair. This also results in a depletion of nicotinamide adenine dinucleotide and adenosine triphosphate (ATP). Cladribine is cell-cycle nonspecific.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~9 L/kg; penetrates CSF (CSF concentrations are ~25% of plasma concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: After a 2-hour infusion (with normal renal function): 5.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (18%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98, 170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernard F, Thomas C, Bertrand Y, et al, &ldquo;Multi-Centre Pilot Study of 2-Chlorodeoxyadenosine and Cytosine Arabinoside Combined Chemotherapy in Refractory Langerhans Cell Histiocytosis With Haematological Dysfunction,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2005, 41(17):2682-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/16291085/pubmed\" id=\"16291085\" target=\"_blank\">",
"        16291085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Byrd JC, Peterson B, Piro L, et al, &ldquo;A Phase II Study of Cladribine Treatment for Fludarabine Refractory B Cell Chronic Lymphocytic Leukemia: Results From CALGB Study 9211,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2003, 17(2):323-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/12592330/pubmed\" id=\"12592330\" target=\"_blank\">",
"        12592330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crews KR, Gandhi V, Srivastava DK, et al, &ldquo;Interim Comparison of a Continuous Infusion versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(20):4217-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/12377965/pubmed\" id=\"12377965\" target=\"_blank\">",
"        12377965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos MA, Kantarjian H, Weber D, et al, &ldquo;Primary Therapy of Waldenstr&ouml;m's Macroglobulinemia With 2-Chlorodeoxyadenosine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(12):2694-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/7989946/pubmed\" id=\"7989946\" target=\"_blank\">",
"        7989946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodman GR, Burian C, Koziol JA., et al, &ldquo;Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(5):891-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/12610190/pubmed\" id=\"12610190\" target=\"_blank\">",
"        12610190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holowiecki J, Grosicki S, Giebel S, et al, \"Cladribine, but not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(20):2441-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/22508825/pubmed\" id=\"22508825\" target=\"_blank\">",
"        22508825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inwards DJ, Fishkin PA, Hillman DW, et al, &ldquo;Long-Term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(1):108-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/18470909/pubmed\" id=\"18470909\" target=\"_blank\">",
"        18470909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krance RA, Hurwitz CA, Head DR, et al, &ldquo;Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(11):2804-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/11387351/pubmed\" id=\"11387351\" target=\"_blank\">",
"        11387351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laszlo D, Andreola G, Rigacci L, et al, &ldquo;Rituximab and Subcutaneous 2-Chloro-2'-Deoxyadenosine Combination Treatment for Patients With Waldenstr&ouml;m Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(13):2233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/20368573/pubmed\" id=\"20368573\" target=\"_blank\">",
"        20368573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ravandi F, O'Brien S, Jorgensen J, et al, \"Phase 2 Study of Cladribine Followed by Rituximab in Patients With Hairy Cell Leukemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(14):3818-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/21821712/pubmed\" id=\"21821712\" target=\"_blank\">",
"        21821712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robak T, &ldquo;Cladribine in the Treatment of Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2001, 40(5-6):551-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/11426528/pubmed\" id=\"11426528\" target=\"_blank\">",
"        11426528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robak T, Jamroziak K, Gora-Tybor J, et al, \"Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide as First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study),\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(11):1863-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/20212251/pubmed\" id=\"20212251\" target=\"_blank\">",
"        20212251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robak T, Wrzesie��-Ku�� A, Lech-Mara��da E, et al, &ldquo;Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2000, 39(1-2):121-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/10975390/pubmed\" id=\"10975390\" target=\"_blank\">",
"        10975390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubnitz JE, Crews KR, Pounds S, et al, &ldquo;Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St Jude AML97 Trial,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2009, 23(8):1410-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/19242495/pubmed\" id=\"19242495\" target=\"_blank\">",
"        19242495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rummel MJ, Chow KU, J&auml;ger E, &ldquo;Treatment of Mantle Cell Lymphomas With Intermittent Two-Hour Infusion of Cladribine as First-Line Therapy or in First Relapse,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 1999, 10(1):115-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/10076731/pubmed\" id=\"10076731\" target=\"_blank\">",
"        10076731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saven A, Burian C, Koziol JA, et al, &ldquo;Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 92(6):1918-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/9731048/pubmed\" id=\"9731048\" target=\"_blank\">",
"        9731048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saven A, Lemon RH, Kosty M, et al, &ldquo;2-Chlorodeoxyadenosine Activity in Patients With Untreated Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(3):570-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/7884417/pubmed\" id=\"7884417\" target=\"_blank\">",
"        7884417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sigal DS, Miller HJ, Schram ED, et al, &ldquo;Beyond Hairy Cell: The Activity of Cladribine in Other Hematologic Malignancies,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(16):2884-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/20634380/pubmed\" id=\"20634380\" target=\"_blank\">",
"        20634380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sigal DS, Sharpe R, Burian C, et al, &ldquo;Very Long-Term Eradication of Minimal Residual Disease in Patients With Hairy Cell Leukemia After a Single Course of Cladribine,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(10):1893-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/20056789/pubmed\" id=\"20056789\" target=\"_blank\">",
"        20056789",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stine KC, Saylors RL, Saccente S, et al, &ldquo;Efficacy of Continuous Infusion 2-CDA (Cladribine) in Pediatric Patients With Langerhans Cell Histiocytosis,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2004, 43(1):81-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/15170896/pubmed\" id=\"15170896\" target=\"_blank\">",
"        15170896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weitzman S, Braier J, Donadieu J, et al, &ldquo;2'-Chlorodeoxyadenosine (2-CdA) as Salvage Therapy for Langerhans Cell Histiocytosis (LCH). Results of the LCH-S-98 Protocol of the Histiocyte Society,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(7):1271-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/19731321/pubmed\" id=\"19731321\" target=\"_blank\">",
"        19731321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wierzbowska A, Robak T, Pluta A, et al, &ldquo;Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group,&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2008, 80(2):115-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/18076637/pubmed\" id=\"18076637\" target=\"_blank\">",
"        18076637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wrzesie��-Ku�� A, Robak T, Lech-Mara��da E, et al, &ldquo;A Multicenter, Open, Non-Comparative Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia &ndash; a Report of the Polish Adult Leukemia Group (PALG),&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2003, 71(3):155&ndash;62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/22/19815/abstract-text/12930315/pubmed\" id=\"12930315\" target=\"_blank\">",
"        12930315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9272 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19815=[""].join("\n");
var outline_f19_22_19815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708674\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152320\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152286\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152303\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152287\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5527019\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5527020\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152263\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152250\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152266\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152325\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152264\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152316\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152326\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152318\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152269\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152254\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299054\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219339\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152281\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152259\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3016299\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152293\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3016301\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323071\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152261\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038562\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152253\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152268\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9272\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9272|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/22/19813?source=related_link\">",
"      Cladribine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/10/11430?source=related_link\">",
"      Cladribine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_22_19816="Endoscopic methods for the diagnosis of pancreatobiliary neoplasms";
var content_f19_22_19816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19816/contributors\">",
"     Susana Escalante-Glorsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19816/contributors\">",
"     Isaac Raijman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19816/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19816/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/22/19816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of biliary neoplasms is usually accomplished through a combination of imaging modalities and tissue sampling. Optimal methods to diagnose these tumors depend upon the clinical setting, the characteristics of the individual tests, and the available resources.",
"   </p>",
"   <p>",
"    This topic review will focus primarily on the accuracy of endoscopic methods to diagnose biliary neoplasms. General discussions on the diagnosis of the individual tumors are presented separately on the corresponding topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) permits the visualization of the biliary neoplasms while providing the opportunity to obtain tissue samples and to perform therapeutic maneuvers (such as biliary decompression) when necessary. Thus, it continues to have a central role in the diagnosis and management of biliary neoplasms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radiographic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiographic findings during ERCP can help distinguish benign from malignant neoplasms. Biliary neoplasms typically appear as a stricture during ERCP. However, strictures caused by benign processes (such as pancreatitis) can have the appearance of malignancies and vice versa. In addition, a neoplasm can develop in a long-standing benign stricture and its recognition may be difficult, such as in patients with primary sclerosing cholangitis and chronic pancreatitis. Some of the characteristics of the stricture suggestive of malignancy include a length of more than 10 mm, a ragged contour, and the presence of a fixed filling defect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an abrupt transition from relatively normal to the stricture, so called shouldering, typically located above the stricture.",
"   </p>",
"   <p>",
"    In addition, strictures involving the hilum should raise concerns of malignancy. The majority of hilar strictures are due to either malignancy or extrinsic compression by lymph nodes. Our experience and that reported in the literature supports the view that hilar strictures should be considered malignant until proven otherwise. Exceptions are patients who have recently undergone liver transplantation. Tissue confirmation should be sought in the majority of patients. The clinical setting, radiographic appearance, and cholangiographic findings may be sufficient to establish the diagnosis of malignancy in patients in whom tissue sampling is not feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tissue sampling during ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue sampling of suspected bile duct tumors can be obtained by cytologic brushings, biopsy forceps, bile aspiration, or a combination of all of these modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/1-23\">",
"     1-23",
"    </a>",
"    ]. In patients in whom a plastic stent has been present, the stent can be spun and the cells obtained can be assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Brush cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used method for tissue sampling during ERCP is cytologic brushing (",
"    <a class=\"graphic graphic_picture graphicRef69158 \" href=\"UTD.htm?26/49/27410\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56362 \" href=\"UTD.htm?17/1/17425\">",
"     image 1",
"    </a>",
"    ). Estimates from several studies have suggested that the sensitivity of cytologic brushing alone ranged from 35 to 70 percent while specificity typically exceeded 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/1-23,25,26\">",
"     1-23,25,26",
"    </a>",
"    ]. The following examples from some of the largest and most recent series illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report focused on 86 patients with biliary strictures of unknown etiology who underwent brush cytology [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/1\">",
"       1",
"      </a>",
"      ]. A final diagnosis was achieved in 78 patients based upon intraoperative findings and histological investigation, autopsy, or prolonged follow-up. Strictures were malignant in 57 patients and benign in 21 patients. The sensitivity and specificity for brush cytology was 56 and 90 percent, respectively. The overall accuracy was 65 percent. The positive and negative predictive values were 94 and 43 percent, respectively.",
"     </li>",
"     <li>",
"      Another study included 148 patients who had undergone brush cytology of the bile or pancreatic ducts and in whom a final diagnosis was available from surgical pathologic examination or long-term clinical follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/27\">",
"       27",
"      </a>",
"      ]. The overall accuracy of biliary and pancreatic cytology was 64 and 72 percent, respectively.",
"     </li>",
"     <li>",
"      A third series included 74 patients with pancreaticobiliary strictures who underwent brush cytology performed on 55 bile and 19 pancreatic duct specimens, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/28\">",
"       28",
"      </a>",
"      ]. The diagnosis was confirmed by surgery, autopsy, or during follow-up. The sensitivity, specificity, positive and negative predictive values were 56, 100, 100, and 51 percent, respectively with an overall accuracy of 70 percent.",
"     </li>",
"     <li>",
"      In a study of 58 patients with hilar cholangiocarcinoma, a malignancy was demonstrated by brush cytology in 40 percent of patients and biopsy forceps in 53 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/29\">",
"       29",
"      </a>",
"      ]. The combination increased the yield to 60 percent (35 of 58 patients).",
"     </li>",
"     <li>",
"      A novel approach to cytology using a brush was suggested in a study in which the brush was cut after obtaining cytologic specimens, immersed in methanol, and then embedded in paraffin [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/30\">",
"       30",
"      </a>",
"      ]. Sections were cut along the axis of the brush until the metal wire was almost reached. Using this technique in 112 consecutive patients with a biliary tract stricture had a sensitivity and specificity of 91 and 100 percent, respectively, when the diagnosed was confirmed histologically. In nonoperated patients, sensitivity and specificity were 96 and 100 percent, respectively, compared with the clinical outcome as the reference standard.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Scraping cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another variation of cytologic examination was proposed in which a guidewire was inserted into pancreatic ductal strictures and subsequently pancreatic juice was collected above the strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/31\">",
"     31",
"    </a>",
"    ]. In a report of 86 patients with pancreatic ductal strictures (71 malignant), sensitivity and specificity were 93 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing a diagnosis of malignancy can be particularly difficult in patients with primary sclerosing cholangitis (PSC). Several approaches have been proposed but their effectiveness remains unsettled. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 61 patients with PSC who underwent liver transplantation, cytological specimen classifications were compared with bile duct histopathological findings in explanted livers [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/32\">",
"       32",
"      </a>",
"      ]. The sensitivity and specificity of cytological low-grade and high grade",
"      <span class=\"nowrap\">",
"       dysplasia/adenocarcinoma",
"      </span>",
"      were 100 and 84 percent, compared with 73 and 95 percent for high-grade",
"      <span class=\"nowrap\">",
"       dysplasia/adenocarcinoma",
"      </span>",
"      only.",
"     </li>",
"     <li>",
"      In a study of 230 patients with PSC followed for a 6-year period, 10 percent developed pathologically confirmed cholangiocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/33\">",
"       33",
"      </a>",
"      ]. The combination of a serum tumor marker (CA 19-9), when combined with a cross imaging study of the liver, such as ultrasound, tomography, or magnetic resonance, provided a better sensitivity than tumor marker alone, but without improvement in the specificity and either positive or negative predictive values. Adding cholangiography increased specificity and positive predictive value.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tumor type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of brush cytology is influenced by the type of tumor. As a general rule, the sensitivity is lower for tumors that do not originate from the biliary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. Primary biliary cancers usually have associated mucosal changes that facilitate acquisition of cells, whereas pancreatic or other metastatic tumors may only produce biliary stricture by extrinsic compression, leaving the bile duct mucosa intact and thus reducing cell acquisition. In the study discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/1\">",
"     1",
"    </a>",
"    ], for example, the sensitivity was significantly higher for cholangiocarcinoma compared with pancreatic carcinoma (80 versus 35 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the tumor type, the accuracy of brush cytology is influenced by the technique of the endoscopist obtaining the brushings and the cytologist interpreting the results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/5,6,34\">",
"     5,6,34",
"    </a>",
"    ]. False positive results may be more likely in patients with strictures arising from inflammatory processes (such as chronic pancreatitis, possibly PSC, and after manipulation and secondary local trauma, such as after sphincterotomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/25\">",
"     25",
"    </a>",
"    ]. Some reports suggested that the disruption of malignant strictures by dilation enhanced the diagnostic yield of bile cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/13,35-38\">",
"     13,35-38",
"    </a>",
"    ]. Repeat brushings are generally indicated with negative results when the clinical or radiographic findings suggest malignancy. The finding of atypical hyperplasia should also raise concern for an underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We advance the brush approximately 10 times over the stricture by moving the brush and the endoscope. When we suspect pancreatic cancer, we brush both the biliary and pancreatic ducts using a standard brush (using a different brush in each duct) although this tends to increase procedural time. We have found that all the commercially available brushes have equivalent efficacy in obtaining tissues. Once the samples have been obtained, we cut the brush head off and drop it in fixative immediately after removing it from the patient. In our experience cutting the brush head off appears to be more sensitive (unpublished data) compared with preparing slides and fixing them in the endoscopy suite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     New tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innovative tools to improve the yield of brush cytology continue to be described. One study compared a longer cytology brush (Cytolong brush, Cook Endoscopy, Winston-Salem, NC) with a standard cytology brush (Geenen brush, Cook Endoscopy, Winston-Salem, NC) in patients with suspected malignant obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/39\">",
"     39",
"    </a>",
"    ]. The brush is 3 mm in diameter, 5 cm long, with stiffer bristles than a standard cytology brush. The bristles are oriented at 45 degrees on a 7F sheath. By contrast, the standard brush is 1.5 cm long, and has bristles oriented at 90 degrees on a 6F sheath. All patients underwent sampling with each of the brushes.",
"   </p>",
"   <p>",
"    The cancer detection rate was not significantly different with the two brushes (27 versus 30 percent). No patient had positive cytology results with CB and negative cytology results with GB. The yield of the two brushes combined was 28 of 94 (30 percent). There was no difference according to stricture location or type of cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Forceps biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue samples can also be obtained during ERCP using a biopsy forceps. Flexible and stiff forceps are available, but the former is preferred since it makes intubation easier. While a prior sphincterotomy is not mandatory, it certainly facilitates ductal intubation and, in many patients undergoing ductal biopsies, a sphincterotomy would have been performed for drainage or stent placement.",
"   </p>",
"   <p>",
"    The sensitivity of forceps biopsy ranged from 43 to 88 percent in various reports, with specificity comparable to brush cytology (ie, &gt;90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/1-23,40,41\">",
"     1-23,40,41",
"    </a>",
"    ]. Whether forceps biopsy alone or in combination with brush cytology is more accurate than brush cytology alone is unclear. One study suggested that the combination of the technique increased the sensitivity by approximately 15 to 25 percent (from 47 to 65 to 70 percent sensitivity) compared with either method alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/8\">",
"     8",
"    </a>",
"    ]. Put another way, this suggests that an endoscopist would have to perform both techniques in four to six patients to detect one tumor that would not have been diagnosed by either method alone. In contrast, another report suggested that the sensitivity of the two techniques was similar (approximately 53 percent) and that the benefit of combining the two techniques (sensitivity of 61 percent) was too small to justify the routine use of the combination approach [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/40\">",
"     40",
"    </a>",
"    ]. There was one bile duct perforation related to forceps biopsy that required surgical oversewing, otherwise both techniques were performed safely. We generally perform both procedures when strictures are located in the intra-ampullary tract, in patients with complete ductal obstruction, or when previous brush cytology alone was negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Endoscopic fine-needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of brush cytology and endobiliary biopsy with endoscopic fine-needle aspiration was more sensitive (73 to 77 percent) than either method alone in at least three reports [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. One study suggested that combining stricture dilation, cytology, and fine-needle aspiration substantially improved the accuracy for diagnosis of malignant strictures caused by gallbladder or pancreatic cancer compared with cytology alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bile aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of bile juice is the simplest method of obtaining a specimen for the evaluation of a stricture. However, sensitivities have been disappointing, ranging from 6 to 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/1,10,26\">",
"     1,10,26",
"    </a>",
"    ]. Some studies suggest that the sensitivity could be improved by dilating the stricture or performing brush cytology prior to bile acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]. Because of the better yield of brush cytology, bile aspiration alone is rarely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expression of tumor markers by biliary neoplasms provided the rationale for studies evaluating the efficacy of their detection during cytologic sampling. A number of markers have been evaluated:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     p53 and K-ras",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated detection of mutations in K-ras and p53 in bile duct specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/14,15,19\">",
"     14,15,19",
"    </a>",
"    ]. One study included 43 patients with primary sclerosing cholangitis in whom 47 brush cytology specimens were obtained from a dominant stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/14\">",
"     14",
"    </a>",
"    ]. Of these, 27 specimens were analyzed for mutations p53 or K-ras. The results were compared with the histologic diagnosis or clinical status at least two years later. The sensitivity, specificity, positive, and negative predictive values of brush cytology alone were 60, 89, 59, and 89 percent, respectively. Adding the results of p53 and K-ras analysis did not improve the results.",
"   </p>",
"   <p>",
"    Similar conclusions were reached in another study assessing the diagnostic value of p53 immunoreactivity in 143 brush cytology specimens from patients with various pancreatobiliary strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/15\">",
"     15",
"    </a>",
"    ]. Sixty-three of 89 (71 percent) malignant strictures were identified cytologically while 45 cases (51 percent) were p53 immunoreactive. Atypical cytology was found cytologically in 19 specimens (13.3 percent), of which p53 expression was positive in 12 cases. Of these 12 cases, four were carcinomas and eight benign. Thus, adding p53 immunostaining did not increase diagnostic accuracy. A third report found no value of K-ras analysis in distinguishing chronic pancreatitis from pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Telomerase RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In situ hybridization for telomerase RNA (found in 85 to 90 percent of malignancies) was evaluated in a study involving 18 patients with benign and malignant biliary strictures, three of whom had cholangiocarcinoma and one who had gallbladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/16\">",
"     16",
"    </a>",
"    ]. Routine cytology was positive in five of eight malignant strictures while telomerase RNA was positive in six (sensitivity 75 percent). Interestingly, both techniques were positive in only three patients.",
"   </p>",
"   <p>",
"    A second study found that 13 of 16 specimens of malignant tissue had telomerase activity compared with none of the nonmalignant specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, p53 over expression was noted by immunostaining in 9 of 16 specimens with malignancy. Combining both telomerase activity and p53 immunoreactivity resulted in sensitivity and specificity of 100 percent. These findings await confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Measures of DNA proliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA proliferation can be assessed with a variety of methods such as digital image analysis (DIA) and fluorescence in situ hybridization (FISH) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/6,20,43-45\">",
"     6,20,43-45",
"    </a>",
"    ]. These techniques show promise in improving the specificity of cytology. DIA quantifies the amount of cellular DNA by measuring the intensity of nuclei stained with a dye that binds to nuclear DNA. FISH uses fluorescently labeled DNA probe test to detect chromosomal abnormalities in cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DIA and FISH were evaluated in a study of 233 consecutive patients undergoing ERCP for a pancreatobiliary stricture. The patients underwent standard cytology, DIA, and FISH [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/43\">",
"     43",
"    </a>",
"    ]. The test performance was similar across groups. Standard cytology had low sensitivity (4 to 20 percent) but 100 percent specificity. In patients with negative cytology, FISH increased sensitivity while preserving specificity. The sensitivity and specificity of DIA was intermediate between routine cytology and FISH.",
"   </p>",
"   <p>",
"    In a study of 235 patients with primary sclerosing cholangitis who underwent FISH, 120 (51 percent) of the patients were positive on FISH testing, but only 40 (33 percent) had cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with polysomy were more likely to have cholangiocarcinoma (26 of 47 patients, 55 percent), especially if a dominant stricture was present (19 of 26 patients, 73 percent). The sensitivity and specificity of polysomy for detecting cholangiocarcinoma were 46 and 88 percent, respectively.",
"   </p>",
"   <p>",
"    Adding DNA measurements as an adjunct to brush cytology in patients with biliary strictures has been suggested to increase diagnostic yield. In a study including 159 patients with bile duct strictures undergoing ERCP, the sensitivity and specificity of DNA aneuploidy for tumor detection were 43 and 96 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/46\">",
"     46",
"    </a>",
"    ]. Adding DNA analysis to brush cytology did not increase the sensitivity.",
"   </p>",
"   <p>",
"    One study evaluated the usefulness of detecting and measuring aberrantly methylated DNA as a marker of pancreatic and periampullary cancers in 130 patients with biliary strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/47\">",
"     47",
"    </a>",
"    ]. Methylation analysis was performed on endoscopically obtained brush samples from the biliary and pancreatic ducts from 130 individuals with biliary tract strictures: 41 with pancreatic ductal adenocarcinoma, 10 with biliary tract cancers, 13 with other periampullary neoplasms, and 66 with non-neoplastic strictures, including 27 with primary sclerosing cholangitis and 39 with other benign strictures. Real-time quantitative methylation-specific polymerase chain reaction was measured in brush DNA. At least one gene positive for methylation by quantitative methylation-specific polymerase chain reaction was observed in 73 percent of patients with pancreatic cancer, 80 percent of those with cholangiocarcinoma compared with 14 percent of those with benign strictures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cholangioscopy during ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miniature endoscopes to visualize the bile (cholangioscopy) or pancreatic (pancreatoscopy) ducts can be used intraoperatively, during ERCP, and percutaneous transhepatic cholangiography. They may have an increasingly important role in the diagnosis and nonsurgical treatment of biliary and pancreatic diseases. At present, these techniques are offered in only a few centers worldwide, where they are most commonly used for tissue sampling of filling defects or strictures in the biliary system, and extraction of intrahepatic stones or biliary parasites and the evaluation of the extent of intraductal pancreatic lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optical coherence tomography (OCT) has been used during cholangioscopy to evaluate biliary strictures and may increase the sensitivity for diagnosing malignant strictures. OCT uses infrared light reflectance to produce high-resolution cross-sectional tissue images. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=see_link\">",
"     \"Optical coherence tomography in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, intraductal OCT was used in 37 patients with biliary strictures to detect malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/48\">",
"     48",
"    </a>",
"    ]. OCT criteria for malignancy included unrecognizable layer architecture and presence of large, non-reflective areas compatible with tumor vessels. Thirty-five of the patients were able to undergo OCT (the remaining two could not due to tight strictures). Of those 35 patients, 19 had malignant strictures and 16 had benign strictures. When both OCT criteria were met, the sensitivity for OCT was 53 percent, with a specificity of 100 percent. If only one criterion was met, the sensitivity was 79 percent, with a specificity of 69 percent. When the results of OCT were combined with the results from biopsies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brushings, the sensitivity increased to 84 percent, with a specificity of 69 percent (the sensitivity and specificity for",
"    <span class=\"nowrap\">",
"     biopsies/brushings",
"    </span>",
"    alone were 79 and 69 percent, respectively).",
"   </p>",
"   <p>",
"    Confocal laser endomicroscopy has also been used in the evaluation of bile duct strictures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=see_link&amp;anchor=H455771716#H455771716\">",
"     \"Confocal laser endomicroscopy and endocytoscopy\", section on 'Bile duct strictures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC ULTRASOUND AND INTRADUCTAL PROBES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endosonography of the biliary tree has not proved as useful as in other parts of the gastrointestinal tract. The technique has only limited ability to characterize the inner layer of the bile duct, to detect invasion of peripheral structures, and to assess the luminal contents of the gallbladder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In addition, extensive experience is required in the performance of echoendoscopy of the bile duct. The addition of fine-needle aspiration biopsy may increase the yield [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 24 patients with proximal biliary strictures and inability to make a diagnosis by brushings, EUS visualized a mass in 23 (96 percent) patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/51\">",
"       51",
"      </a>",
"      ]. EUS-guided fine-needle aspiration (FNA) demonstrated malignancy in 17 of 24 (71 percent) of patients. The overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of EUS-FNA were 77 percent, 100 percent, 100 percent, 29 percent, and 79 percent, respectively.",
"     </li>",
"     <li>",
"      Similar results were obtained in a study 81 patients with cholangiocarcinoma confirmed on surgical pathology who had undergone EUS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/52\">",
"       52",
"      </a>",
"      ]. EUS identified the tumor in 76 patients (94 percent), a rate higher than what was seen with triphasic computed tomography (30 percent), or magnetic resonance imaging (42 percent). EUS-FNA was performed in 74 of the patients (91 percent) and diagnosed cholangiocarcinoma in 54 patients for a sensitivity of 73 percent. The sensitivity was higher for distal lesions than for proximal lesions (81 versus 59 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus EUS FNA is a sensitive method for the diagnosis of proximal biliary strictures after negative brushings but, a negative biopsy does not exclude malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A newly developed forward-viewing linear echoendoscope (FVL-EUS) with FNA was used in four patients with hilar biliary strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/53\">",
"     53",
"    </a>",
"    ]. In all four patients, it was possible to visualize and perform FNA and a definitive tissue diagnosis was obtained in all of the patients. This new echoendoscope appears promising in the evaluation of patients with hilar biliary strictures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intraductal ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal ultrasonography using high frequency transducers has been used to characterize biliary strictures and to distinguish between benign and malignant disease. Criteria that suggest the presence of malignancy include a hypoechoic mass, especially if infiltrating surrounding tissues, heterogeneity of the internal echo, notching or irregularity of the outer border, a papillary surface, or disruption of the normal bile duct structure. Limitations of this technique include its lack of widespread availability, inability to detect mild invasion to the perimuscular loose connective tissue, and its inability to detect lymph node or distal metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=see_link\">",
"     \"Intraductal ultrasound of the pancreaticobiliary ductal system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An illustrative prospective study evaluated cholangiography, routine cytology, digital image analysis (DIA), and fluorescence in situ hybridization (FISH) of tissue samples, and intraductal ultrasound in 86 patients with indeterminate biliary strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19816/abstract/44\">",
"     44",
"    </a>",
"    ]. The combination of DIA, FISH, and intraductal ultrasound increased the yield several-fold compared with routine cytology and histology alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of biliary tract malignancies is based upon the combination of clinical presentation, laboratory data, imaging and tissue sampling techniques. The choice among these depends in part upon the tumor location, available expertise, and the clinical settings. Combination approaches are usually required including endosonography, ERCP",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MRCP, and combination of brush cytology, biopsy, and aspiration. The availability of newer choledochoscopes that are easier to maneuver, require only one endoscopist, and can be readily available within minutes while performing ERCP will have a significant impact on the diagnosis of malignancy as well as local staging of cholangiocarcinoma.",
"     </li>",
"     <li>",
"      Despite the available techniques, the diagnosis may remain elusive. In some cases, the diagnosis can be confirmed histologically only after surgery.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/1\">",
"      Kurzawinski TR, Deery A, Dooley JS, et al. A prospective study of biliary cytology in 100 patients with bile duct strictures. Hepatology 1993; 18:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/2\">",
"      Sch&ouml;fl R. Diagnostic endoscopic retrograde cholangiopancreatography. Endoscopy 2001; 33:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/3\">",
"      Trent V, Khurana KK, Pisharodi LR. Diagnostic accuracy and clinical utility of endoscopic bile duct brushing in the evaluation of biliary strictures. Arch Pathol Lab Med 1999; 123:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/4\">",
"      Lee JG, Leung JW, Baillie J, et al. Benign, dysplastic, or malignant--making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. Am J Gastroenterol 1995; 90:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/5\">",
"      Logrono R, Kurtycz DF, Molina CP, et al. Analysis of false-negative diagnoses on endoscopic brush cytology of biliary and pancreatic duct strictures: the experience at 2 university hospitals. Arch Pathol Lab Med 2000; 124:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/6\">",
"      Rumalla A, Baron TH, Leontovich O, et al. Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis. Mayo Clin Proc 2001; 76:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/7\">",
"      Pugliese V, Antonelli G, Vincenti M, Gatteschi B. Endoductal tissue sampling of biliary strictures through endoscopic retrograde cholangiopan creatography (ERCP). Tumori 1997; 83:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/8\">",
"      Schoefl R, Haefner M, Wrba F, et al. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. Scand J Gastroenterol 1997; 32:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/9\">",
"      Parasher VK, Huibregtse K. Endoscopic retrograde wire-guided cytology of malignant biliary strictures using a novel scraping brush. Gastrointest Endosc 1998; 48:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/10\">",
"      Fogel EL, Sherman S. How to improve the accuracy of diagnosis of malignant biliary strictures. Endoscopy 1999; 31:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/11\">",
"      Foutch PG. Diagnosis of cancer by cytologic methods performed during ERCP. Gastrointest Endosc 1994; 40:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/12\">",
"      Howell DA, Beveridge RP, Bosco J, Jones M. Endoscopic needle aspiration biopsy at ERCP in the diagnosis of biliary strictures. Gastrointest Endosc 1992; 38:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/13\">",
"      Mohandas KM, Swaroop VS, Gullar SU, et al. Diagnosis of malignant obstructive jaundice by bile cytology: results improved by dilating the bile duct strictures. Gastrointest Endosc 1994; 40:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/14\">",
"      Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/15\">",
"      Stewart CJ, Burke GM. Value of p53 immunostaining in pancreatico-biliary brush cytology specimens. Diagn Cytopathol 2000; 23:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/16\">",
"      Morales CP, Burdick JS, Saboorian MH, et al. In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. Gastrointest Endosc 1998; 48:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/17\">",
"      Itoi T, Shinohara Y, Takeda K, et al. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest Endosc 2000; 52:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/18\">",
"      Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/19\">",
"      Saurin JC, Joly-Pharaboz MO, Pernas P, et al. Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures. Gut 2000; 47:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/20\">",
"      Ryan ME, Baldauf MC. Comparison of flow cytometry for DNA content and brush cytology for detection of malignancy in pancreaticobiliary strictures. Gastrointest Endosc 1994; 40:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/21\">",
"      Tamada K, Sugano K. Diagnosis and non-surgical treatment of bile duct carcinoma: developments in the past decade. J Gastroenterol 2000; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/22\">",
"      Rumalla A, Petersen BT. Diagnosis and therapy of biliary tract malignancy. Semin Gastrointest Dis 2000; 11:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/23\">",
"      Bain VG, Abraham N, Jhangri GS, et al. Prospective study of biliary strictures to determine the predictors of malignancy. Can J Gastroenterol 2000; 14:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/24\">",
"      Adamsen S, Olsen M, Jendresen MB, et al. Endobiliary brush biopsy: Intra- and interobserver variation in cytological evaluation of brushings from bile duct strictures. Scand J Gastroenterol 2006; 41:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/25\">",
"      Glasbrenner B, Ardan M, Boeck W, et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999; 31:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/26\">",
"      Yamaguchi T, Shirai Y, Nakamura N, et al. Usefulness of brush cytology combined with pancreatic juice cytology in the diagnosis of pancreatic cancer: significance of pancreatic juice cytology after brushing. Pancreas 2012; 41:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/27\">",
"      Vandervoort J, Soetikno RM, Montes H, et al. Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct. Gastrointest Endosc 1999; 49:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/28\">",
"      Ferrari J&uacute;nior AP, Lichtenstein DR, Slivka A, et al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc 1994; 40:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/29\">",
"      Weber A, von Weyhern C, Fend F, et al. Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma. World J Gastroenterol 2008; 14:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/30\">",
"      Asioli S, Accinelli G, Pacchioni D, Bussolati G. Diagnosis of biliary tract lesions by histological sectioning of brush bristles as alternative to cytological smearing. Am J Gastroenterol 2008; 103:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/31\">",
"      Uehara H, Tatsumi K, Masuda E, et al. Scraping cytology with a guidewire for pancreatic-ductal strictures. Gastrointest Endosc 2009; 70:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/32\">",
"      Boberg KM, Jebsen P, Clausen OP, et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006; 45:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/33\">",
"      Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/34\">",
"      McGuire DE, Venu RP, Brown RD, et al. Brush cytology for pancreatic carcinoma: an analysis of factors influencing results. Gastrointest Endosc 1996; 44:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/35\">",
"      Farrell RJ, Jain AK, Brandwein SL, et al. The combination of stricture dilation, endoscopic needle aspiration, and biliary brushings significantly improves diagnostic yield from malignant bile duct strictures. Gastrointest Endosc 2001; 54:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/36\">",
"      de Bellis M, Fogel EL, Sherman S, et al. Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc 2003; 58:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/37\">",
"      Ornellas LC, Santos Gda C, Nakao FS, Ferrari AP. Comparison between endoscopic brush cytology performed before and after biliary stricture dilation for cancer detection. Arq Gastroenterol 2006; 43:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/38\">",
"      de Bellis M, Sherman S, Fogel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 2). Gastrointest Endosc 2002; 56:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/39\">",
"      Fogel EL, deBellis M, McHenry L, et al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. Gastrointest Endosc 2006; 63:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/40\">",
"      Pugliese V, Conio M, Nicol&ograve; G, et al. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc 1995; 42:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/41\">",
"      Sugiyama M, Atomi Y, Wada N, et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996; 91:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/42\">",
"      Pugliese V, Pujic N, Saccomanno S, et al. Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases. Gastrointest Endosc 2001; 54:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/43\">",
"      Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/44\">",
"      Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008; 103:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/45\">",
"      Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010; 51:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/46\">",
"      Lindberg B, Enochsson L, Tribukait B, et al. Diagnostic and prognostic implications of DNA ploidy and S-phase evaluation in the assessment of malignancy in biliary strictures. Endoscopy 2006; 38:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/47\">",
"      Parsi MA, Li A, Li CP, Goggins M. DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol 2008; 6:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/48\">",
"      Arvanitakis M, Hookey L, Tessier G, et al. Intraductal optical coherence tomography during endoscopic retrograde cholangiopancreatography for investigation of biliary strictures. Endoscopy 2009; 41:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/49\">",
"      Inui K, Nakazawa S, Yoshino J, et al. Ultrasound probes for biliary lesions. Endoscopy 1998; 30 Suppl 1:A120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/50\">",
"      Tamada K, Ido K, Ueno N, et al. Preoperative staging of extrahepatic bile duct cancer with intraductal ultrasonography. Am J Gastroenterol 1995; 90:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/51\">",
"      DeWitt J, Misra VL, Leblanc JK, et al. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc 2006; 64:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/52\">",
"      Mohamadnejad M, DeWitt JM, Sherman S, et al. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. Gastrointest Endosc 2011; 73:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19816/abstract/53\">",
"      Larghi A, Lecca PG, Ardito F, et al. Evaluation of hilar biliary strictures by using a newly developed forward-viewing therapeutic echoendoscope: preliminary results of an ongoing experience. Gastrointest Endosc 2009; 69:356.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 648 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19816=[""].join("\n");
var outline_f19_22_19816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radiographic appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tissue sampling during ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Brush cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Scraping cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tumor type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - New tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Forceps biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Endoscopic fine-needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bile aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - p53 and K-ras",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Telomerase RNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Measures of DNA proliferation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cholangioscopy during ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ENDOSCOPIC ULTRASOUND AND INTRADUCTAL PROBES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intraductal ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/648\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/648|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/1/17425\" title=\"diagnostic image 1\">",
"      Cytology bile duct strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/648|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/49/27410\" title=\"picture 1\">",
"      Cytology brush for ERCP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=related_link\">",
"      Confocal laser endomicroscopy and endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=related_link\">",
"      Intraductal ultrasound of the pancreaticobiliary ductal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=related_link\">",
"      Optical coherence tomography in the gastrointestinal tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_22_19817="Overview of anesthesia and anesthetic choices";
var content_f19_22_19817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of anesthesia and anesthetic choices",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19817/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19817/contributors\">",
"     Scott A Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19817/contributors\">",
"     Lee A Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19817/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19817/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/22/19817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The state of \"anesthesia\" means different things to different individuals and is as much a philosophical state as a neuro-scientific one. While the definition of anesthesia itself, as the loss of \"awareness,\" is rather vague, a pragmatic definition of anesthesia as the provision of a combination of amnesia, analgesia (pain control), and muscle relaxation to allow the performance of surgery or interventional procedures is more useful. Anesthesiologists are also responsible for physiologic homeostasis while the patient is in the anesthetized state providing for the safest and most comfortable perioperative experience possible.",
"   </p>",
"   <p>",
"    Anesthesiologists and the anesthesia care team, including Certified Registered Nurse Anesthetists (CRNAs) and Anesthesia Assistants (AAs), work to provide a wide range of perioperative services including preoperative evaluation, intraoperative management, post-operative management, intensive care unit (ICU) care, and acute and chronic pain management. The consultant anesthesiologist will function to some degree in all these roles in each patient",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    takes care of, taking into consideration numerous factors when deciding on an anesthetic plan with the surgeon and patient.",
"   </p>",
"   <p>",
"    This topic discusses an overview of anesthesia and anesthetic choices focusing on intraoperative management and the risks and benefits of anesthetic choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of anesthesia is the maintenance of physiologic homeostasis. This includes monitoring and treatment of cardiovascular, pulmonary, neurologic and renal functions and changes during the perioperative period to minimize adverse outcomes. Optimizing intraoperative physiology may help speed recovery and provide for perioperative organ system protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Amnesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnesia refers to the lack of memory of the intraoperative and perioperative experience. It is reliably achieved by inducing a state of unconsciousness as a result of general anesthesia. A three year study including 87,361 patients found six patients reporting recall under general anesthesia (incidence 0.0068 percent, or 1 per 14,560) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/1\">",
"     1",
"    </a>",
"    ]. This is the largest study to date looking at recall under general anesthesia. The rate of 1 in 14,560 is lower than the 0.1 and 0.9 percent rate generally reported in the literature; however, previous studies have generally focused on specific patient populations at higher risk for recall, such as obstetric, trauma or cardiac patients, while this study included a wide range of procedures. Differences may also be due to observer or surveyor bias, and perceived differences in implicit versus explicit awareness.",
"   </p>",
"   <p>",
"    In addition, anesthesiologists now have better tools available for physiologic monitoring, such as end-tidal carbon dioxide (ETCO2), pulse oximetry, and anesthetic gas monitoring, which help define a safe threshold for maximal anesthetic delivery.",
"   </p>",
"   <p>",
"    Emergency surgery for polytrauma carries a higher incidence of recall due to the \"lighter\" anesthetic used in these unstable patients. Other risk factors for intraoperative awareness include depression, cesarean delivery, and cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The most likely cause of awareness is a \"lighter\" depth of anesthesia, which may be necessary in urgent or emergent inductions in potentially unstable patients in order to maintain blood pressure and organ perfusion. The physiologic reason for increased intraoperative awareness in patients with depressive disorder is not clear, but probably is a result of complex neurochemical interactions.",
"   </p>",
"   <p>",
"    In certain circumstances amnesia may be undesirable and may be avoided by utilizing a regional anesthetic technique. The classic example is during a cesarean delivery under a neuraxial anesthetic; most mothers want to have memory of the birth of their child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain control is an essential part of perioperative management. The most common methods of providing pain relief include local anesthesia, parenteral narcotics, and nonsteroidal antiinflammatory drugs (NSAIDs), neuraxial blockade with epidural or spinal anesthetics, or regional nerve blockade. There are many ways to achieve perioperative analgesia in patients, depending on the surgical procedure, underlying medical problems, risk associated with the method, and, to some degree, patient preferences. For example, patients undergoing surgery for abdominal cancer had better pain relief with an epidural infusion compared to intravenous narcotics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multimodal or balanced analgesia employs more than one modality of pain control to obtain additive or synergistic beneficial analgesia while reducing the undesirable side effects of opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/5\">",
"     5",
"    </a>",
"    ]. It may involve systemic administration of analgesic drugs with different mechanisms of action, but can also include the concurrent use of regional analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/5\">",
"     5",
"    </a>",
"    ]. This approach reduces the length of in-hospital stay and return to full activity sooner after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuromuscular blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important requirements for optimal operating conditions is that the patient remains still during surgery. This goal can be achieved using different techniques, the most popular of which is neuromuscular blockade. Neuromuscular blocking agents block the acetylcholine receptors at the neuromuscular junctions of striated muscle to provide \"relaxation\" of the major muscle groups in the body. These medications do not have effects on smooth or cardiac muscle and are associated with few adverse effects when used judiciously. A balanced anesthetic technique, using a combination of volatile anesthetics, analgesics, and benzodiazepines achieves excellent immobility and analgesia without necessitating the use of neuromuscular blocking agents. Neuraxial or peripheral nerve blocks provide excellent anesthesia during surgery of the extremities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TYPES OF ANESTHESIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;General anesthesia (GA) is appropriate for most complex surgical procedures. A general anesthetic can be divided into three distinct phases: induction, maintenance, and emergence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of general anesthesia for adults is usually achieved with the injection of intravenous medications. The most commonly used induction agent in the United States is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    because of its favorable recovery profile and short elimination half-life (resulting in less prolonged sedation and less nausea than sodium pentothal, a barbiturate induction agent). A study of over 4000 patients found an 18 percent reduction in postoperative nausea and vomiting with propofol compared propofol to sodium pentothal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/6\">",
"     6",
"    </a>",
"    ]. When used for induction, propofol causes bradycardia and hypotension in 4.2 percent and 15.7 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other less common induction agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    . These agents have lower rates of hemodynamic instability than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and may be used in specific situations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      may be used when vasodilation and cardiac depression are particularly undesirable, since etomidate does not cause profound hypotension. Etomidate causes a burning sensation on administration and a higher rate of postoperative nausea than other anesthetics. A significant cautionary drawback to the use of etomidate is that even a single dose can cause adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H12#H12\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      is a phencyclidine derivative and rapid acting dissociative general anesthetic. The benefits of ketamine include significant analgesia and preservation of respiratory drive. Ketamine also causes bronchodilation, which may be beneficial in patients with reactive airways. Used alone, it may have cardiovascular stimulant properties",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unpleasant emergence reactions such as hallucinations, vivid dreams, or delirium. Benzodiazepines can be used in combination with ketamine to reduce these side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of anesthesia can be achieved with volatile or intravenous (IV) anesthetics. Volatile agents remain a popular choice among anesthesiologists because of their ease of delivery, reliable recovery, excellent safety profile, and modest cost.",
"   </p>",
"   <p>",
"    The most severe adverse effect of all the volatile anesthetics is fulminant hepatic necrosis caused by halothane. The incidence of this rare event was 1 in 35,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/10\">",
"     10",
"    </a>",
"    ]. The now more widely used halogenated volatile anesthetics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    have been associated with only isolated case reports of hepatotoxicity. In most of these cases, there was some degree of underlying hepatic pathology.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    has been used in combination with volatile anesthetic agents. Nitrous oxide is fairly insoluble, providing the advantage of quick and reliable recovery, and less myocardial depression. However, the incidence of adverse reactions to nitrous oxide is probably more significant than previously thought. Common adverse reactions include nausea and diffusional hypoxemia upon emergence from anesthesia. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Emergence'",
"    </a>",
"    below.) In addition, the relative insolubility of nitrous oxide compared to nitrogen can cause expansion of air filled compartments in the body, with adverse effects such as rupture of pulmonary blebs (pneumothorax) or further expansion of an existing pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    inactivates vitamin B12 with deleterious effects in selected patients. There have been at least five case reports of severe neurodegeneration when administering nitrous oxide to vitamin B12 deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/12\">",
"     12",
"    </a>",
"    ]. Vitamin B12 inactivation induced by nitrous oxide can also cause megaloblastic changes in the bone marrow and peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/11\">",
"     11",
"    </a>",
"    ]. These effects may be particularly important in children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maintenance of the anesthetized state with intravenous anesthetics is rapidly becoming a popular alternative to volatile gas anesthesia for certain procedures (eg, breast biopsy) and a necessity for procedures like bronchoscopy. Continuous infusions of one or a combination of medications are used to provide amnesia and analgesia. A typical regimen involves the combined administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    , two relatively short-acting intravenous agents.",
"   </p>",
"   <p>",
"    The efficacy of total intravenous anesthesia (TIVA) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    was compared to volatile gas anesthesia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    (plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) in a randomized trial of 49 patients undergoing elective abdominal prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/14\">",
"     14",
"    </a>",
"    ]. TIVA was associated with a significant reduction in the incidence of postoperative nausea and vomiting (zero versus 33 percent). On the other hand, the times to extubation and return of cognitive function were significantly longer with TIVA (by 5 to 6 minutes). There were no significant differences in postanesthetic care unit (PACU) discharge times or mini-mental status scores between the groups. Overall costs were higher in the TIVA group (59 versus 35 Euros).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Emergence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergence or \"waking up\" from general anesthesia is a crucial time in which the anesthesiologist welcomes the patient back to a restored state of consciousness. With this return of consciousness there is a short period of time in which the patient's body is aware of the emergence without a full return to consciousness. This results in autonomic hyper-responsiveness which may manifest as hypertension, tachycardia, bronchospasm, or laryngospasm. Short acting narcotics, beta blockers, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    can blunt these responses in patients, when these responses may be harmful (eg ischemic heart disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuraxial anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal or epidural anesthesia may be used as a primary anesthetic for patients undergoing surgery of the lower extremities or abdomen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37574?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Options\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of postoperative pain\", section on 'Neuraxial (regional) analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Spinal anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;To perform spinal anesthesia a small gauge needle is inserted into a lumbar (usually L3-L4 or L4-L5) interspace until it reaches the subarachnoid space. Next, local anesthetic is injected to produce temporary numbness and muscle relaxation. The anesthetic duration and dermatomal level of blockade can be adjusted by using different local anesthetics and adjusting baricity and patient position.",
"   </p>",
"   <p>",
"    Spinal anesthesia is most popular for lower extremity orthopedic procedures in appropriate patients. A comparison of general anesthesia and spinal anesthesia for total hip arthroplasty demonstrated a decrease in surgical time by 12 percent, blood loss by 25 percent, and intraoperative transfusion requirement by 50 percent when using spinal anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of spinal anesthesia may decrease the incidence of thrombotic phenomena such as deep venous thrombosis (DVT) or pulmonary embolus (PE), which are a major cause of postoperative morbidity in lower extremity surgery. In one study, the incidence of DVT by venogram was 40 percent in the spinal anesthesia group versus 76 percent in the general anesthesia group after repair of femoral neck fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/16\">",
"     16",
"    </a>",
"    ]. It should be noted that this study was published prior to the routine use of perioperative thromboprophylaxis which has reduced the rate of thrombotic complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Epidural anesthesia and analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural anesthesia is achieved with the placement of a small gauge flexible catheter into the epidural space via a needle using either a loss of resistance (more commonly used) or hanging drop technique. Repeat dosing of local anesthetic and adjunctive medications for prolonged intraoperative management is possible by leaving a catheter in the central neuraxial space for infusion. Furthermore, this catheter may remain in place for postoperative analgesia.",
"   </p>",
"   <p>",
"    Studies comparing general anesthesia versus epidural anesthesia for lower extremity vascular surgery and inguinal herniorrhaphy have noted a decrease in both platelet aggregation and overall perioperative stress responses when using epidural anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Because of the favorable effect on perioperative stress response, epidural catheters may be used in combination with general anesthesia to provide analgesia even if not used as the primary anesthetic.",
"   </p>",
"   <p>",
"    Epidural analgesia has been shown to be beneficial in several situations. In patient undergoing major aortic surgery, patients receiving combined of general and epidural analgesia had a significantly lower incidence of death and major perioperative complications (myocardial infarction, stroke, respiratory failure) than the general anesthesia only group (22 versus 37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of neuraxial anesthesia are associated with some risks, which are uncommon but can be serious. The most common adverse event associated with neuraxial blockade is post-dural puncture headache.",
"   </p>",
"   <p>",
"    The incidence of dural puncture with the larger epidural insertion needles is close to 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/20\">",
"     20",
"    </a>",
"    ], whereas, the incidence of post-dural puncture headache after spinal anesthesia is lower because small gauge pencil point needles are more commonly used. A prospective, blinded, randomized trial of over 1000 obstetric patients compared Quincke and Atruacan cutting needles to pencil point needles (Gertie Marx, Sprotte and Whitacre) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/21\">",
"     21",
"    </a>",
"    ]. There was a significantly lower rate of post-dural puncture headache in the pencil point group (2.8 to 4 percent versus 5 to 9 percent).",
"   </p>",
"   <p>",
"    The incidence of spinal hematoma and epidural abscess after neuraxial anesthesia has been noted to be 0.05 and 0.1 percent with the need for operative intervention at 0.01 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/22\">",
"     22",
"    </a>",
"    ]. There is some controversy regarding the level of anticoagulation at which the incidence of spinal hematomas outweighs the benefit of neuraxial anesthesia. This is a decision that should ultimately be left to the consulting anesthesiologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should not influence the decision to place a neuraxial block [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    has been associated with several case reports of epidural hematomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The American Society of Regional Anesthesia and Pain Medicine (ASRA) currently recommends a waiting period of 14 days between the last dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    and 7 days after the last dose of clopidogrel before the placement of a neuraxial block [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Peripheral nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective nerve blocks are another anesthetic option commonly used for procedures involving the extremities. The most common nerve groups blocked are the brachial plexus (interscalene block, infraclavicular block, axillary block), the sciatic nerve (posterior or lateral approach), and the femoral nerve group (3 in 1 block). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=see_link\">",
"     \"Overview of peripheral nerve blocks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selective nerve blocks may be used for operative anesthesia or post-operative pain control. The major advantage of selective nerve blockade is relaxation and analgesia of the selected area without the hemodynamic instability associated with general anesthesia or neuraxial blockade.",
"   </p>",
"   <p>",
"    The safety of these procedures has improved dramatically with the use of nerve stimulators and ultrasound guidance for needle and catheter placements. A study of 1398 patients noted the incidence of local inflammation to be 0.6 percent, local infection to be 0.2 percent, with no serious cases of neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/27\">",
"     27",
"    </a>",
"    ]. There was one retroperitoneal hematoma noted in the study group with an incidence of inadvertent vascular puncture of 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3483410\">",
"    <span class=\"h2\">",
"     Intravenous regional block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous regional block (Bier block) is an alternative to peripheral nerve block for extremity surgery, usually the hand or forearm. This technique can also be applied in pain therapy (eg, chronic regional pain syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique uses a 20 to 22 gauge intravenous cannula placed usually in the hand for administration of local anesthetic in conjunction with one double tourniquet or two single pneumatic tourniquets placed proximally in the arm. The tourniquets must be auto-insufflating to maintain a fixed pre-determined pressure.",
"   </p>",
"   <p>",
"    After the intravenous cannula and tourniquets are in place, the extremity is exsanguinated from distal to proximal using an Esmarch bandage. The tourniquet is inflated. When the pressure in the tourniquet is stable, the Esmarch bandage is removed. Local anesthetic (0.5%) is injected into the intravenous line. Signs and symptoms of anesthesia (numbness, insensitivity) develop in three to five minutes followed by motor paralysis. If the surgery is to involve the hand, the intravenous cannula is removed before the hand is prepped and draped. If tourniquet pain becomes an issue, a second tourniquet can be placed within the zone of anesthesia and inflated and the more proximal tourniquet that is causing discomfort deflated. Insufflation times are limited to a maximum of 1.5 to 2 hours, and the insufflation time should not be less than 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/28\">",
"     28",
"    </a>",
"    ]. Although if the procedure takes less time than anticipated, the tourniquet can be can very briefly partially deflated and then reinflated to gradually release the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for systemic breakdown.",
"   </p>",
"   <p>",
"    The inflation pressure of pneumatic tourniquets is debated. Tourniquet pressures exceeding 150 mmHg of the systolic pressure cannot guarantee the absence of systemic local anesthetic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/29\">",
"     29",
"    </a>",
"    ]. Tourniquet pressures that are 100 mmHg greater than brachial systolic pressure should be adequate. For most patients, insufflation pressure of 250 mmHg for the upper extremity, 300 mmHg for the lower extremity, and 230 mmHg in pediatric patients can be used.",
"   </p>",
"   <p>",
"    The volume of local anesthetic required to achieve the block using the dilute concentration of local anesthetic (0.5%) is about 40 to 50 mL for the upper extremity and 60 to 80 mL for the lower extremity injected at a rate of 3",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef51777 \" href=\"UTD.htm?29/24/30092\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once the tourniquet is released, sensation returns quickly. Because of the rapid recovery, intravenous regional anesthesia is useful for patients undergoing ambulatory or emergency department procedures of the extremities.",
"   </p>",
"   <p>",
"    Although the technique has a high degree of safety, serious toxic reactions to local anesthetic occur in about 1.6 percent of patients and include somnolence, incoherence, seizures, and cardiac arrest. These are typically due to accidental cuff deflation within 20 min of local anesthetic injection, but have also been reported during tourniquet inflation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link&amp;anchor=H2694642#H2694642\">",
"     \"Infiltration of local anesthetics\", section on 'Systemic toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other complications include self-limited skin discoloration or petechiae, thrombophlebitis, compartment syndrome and nerve damage. Treatment of these complications is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link&amp;anchor=H20#H20\">",
"     \"Superficial thrombophlebitis of the lower extremity\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monitored anesthesia care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitored anesthesia care (MAC) is an amorphous spectrum of perioperative services which generally includes intraoperative physiologic monitoring, provision of analgesia and anxiolysis, and further intervention and support as necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/31\">",
"     31",
"    </a>",
"    ]. Classically, MAC anesthesia does not involve complete loss of consciousness and patients should be made aware that they have a high likelihood of intraoperative recall. The surgeon needs to provide adequate local anesthesia for MAC to be successful since sedation does not ensure pain control. The patient should also understand that they will feel pushing and pulling although they should not experience sharp pain providing the local anesthesia is adequate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Anesthesiologists (ASA) makes a clear distinction between moderate or conscious sedation (often administered by non-anesthesiologists) and deep sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/31\">",
"     31",
"    </a>",
"    ]. ASA standards and guidelines are available",
"    <a class=\"external\" href=\"file://www.asahq.org/For-Members/Standards-Guidelines-and-Statements.aspx\">",
"     online",
"    </a>",
"    . The provider of deep sedation must be prepared and qualified to convert to general anesthesia when necessary. By contrast, moderate sedation should not induce such depth of sedation that the patient cannot maintain airway integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study examining the closed claims associated with MAC anesthesia observed that the majority of claims resulted from oversedation and respiratory depression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/32\">",
"     32",
"    </a>",
"    ]. Better monitoring and vigilance would have prevented the majority of these occurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREOPERATIVE RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate assessment of the likelihood of complications is an important part of the preoperative evaluation. It is essential to differentiate between the potential risks solely attributable to administration of anesthesia versus those risks which the anesthesia provider may modify (See individual topic reviews on preoperative risk assessment of patients with specific medical disorders).",
"   </p>",
"   <p>",
"    \"Perioperative\" risk is multifactorial, and depends upon the interaction of anesthesia-, patient- and surgery-specific factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/33\">",
"     33",
"    </a>",
"    ]. With respect to anesthesia, both the effects of the agents and the skills of the anesthetic practitioner are important. Similarly, the nature of the surgical procedure and the surgeon's skill impacts perioperative risk. From the patient's perspective, potential complications of the co-existing disease must be weighed against the risk of anesthetic or surgical complications.",
"   </p>",
"   <p>",
"    In assessing anesthetic risks, several points in time are relevant. Intraoperative morbidity and mortality, any death within 48 hours of an anesthetic, and 30 day morbidity and mortality are time points used in the estimation of anesthetic and surgical risk. With respect to ambulatory surgery, 30 day outcomes may be too long and complications within the first 7 days are more relevant, based upon the pattern of hospital admissions observed in a Medicare population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of the risks, benefits and information provided clearly do not supersede the clinical judgment and expertise of any one anesthesiologist taking care of any specific patient with their unique preferences, fears, and comorbidities. Therefore, the final determination of what anesthetic is appropriate for a given patient is best left to the individual's anesthesiologist who will take into consideration the patient, procedure, practice environment, and care standards for their institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Risk classification systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Anesthesiologists (ASA) physical status classification system is a relatively simple system which has proven effective in stratifying overall preoperative risk of morbidity and mortality for patients undergoing anesthesia and surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are divided according to how their underlying medical problems produce functional impediments to their everyday activities. For example, an ASA class I patient has no underlying conditions or limitations, while a class V patient is not expected to survive the next 24 hours without the proposed intervention (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"     table 2",
"    </a>",
"    ). Risks inherent to a specific procedure are not incorporated into the ASA class.",
"   </p>",
"   <p>",
"    Over the past several decades, anesthesia related mortality rates have reduced from two deaths per 10,000 anesthetic administered to one death per 200,000 to 300,000 anesthetics administered [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. This represents a tremendous improvement over prior mortality rates, a result of careful focus on anesthesia safety. Complications are much more likely to occur in patients with preexisting disease states. The relative risk of serious perioperative complications is 2.2 and 4.4 for ASA patient status III and IV, respectively, illustrating that increasing serious comorbidities (and therefore ASA classification) increases perioperative morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One component of preoperative evaluation is assessment of cardiac risk for patients undergoing noncardiac surgery. A tool commonly used by anesthesiologists and other clinicians involved in pre-operative assessment to stratify and minimize perioperative risk of cardiac events is the American College of Cardiology and American Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/38\">",
"     38",
"    </a>",
"    ]. These guidelines provide an evidence based algorithm for the assessment and treatment of patients' cardiac risk based on risk factors, medical history and testing as well as the surgical risk outlined above. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMMON ANESTHESIA PROCEDURES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Endotracheal intubation",
"      </strong>",
"      &ndash; The placement of an endotracheal tube for airway and ventilatory maintenance is probably the most common procedure performed by anesthesiologists. After induction of anesthesia, a tube is placed via the mouth into the trachea under direct visualization using a laryngoscope (",
"      <a class=\"graphic graphic_figure graphicRef58682 \" href=\"UTD.htm?41/54/42863\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71498 \" href=\"UTD.htm?28/0/28676\">",
"       figure 2",
"      </a>",
"      ). The incidence of difficult intubation, requiring more than one attempt at laryngoscopy, is cited at less than 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. There are many factors which predispose patients to difficulty with airway management including obesity, limited mento-hyoid distance, limited mouth opening, limited mandibular flexibility and limited extension of the cervical spine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"       \"Basic airway management in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"       \"Rapid sequence intubation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"       \"The difficult airway in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=see_link\">",
"       \"Devices for difficult emergency airway management in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Post operative sore throat is the most common adverse event related to endotracheal intubation with an incidence of approximately 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/41\">",
"       41",
"      </a>",
"      ]. Other problems that may be encountered during and after endotracheal intubation include aspiration of gastric contents, dislocation of arytenoid cartilage, and damage to teeth or tracheal mucosa. The risk of pulmonary aspiration for all patients undergoing tracheal intubation for surgery is 2.7 in 10,000 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/42\">",
"       42",
"      </a>",
"      ]. The incidence of aspiration is higher in patients with risk factors such as gastroesophageal dysmotility, gastroesophageal reflux disease, and obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/43\">",
"       43",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Laryngeal mask airway placement",
"      </strong>",
"      &ndash; The laryngeal mask airway (LMA) is a popular tool for maintaining airway patency during general anesthesia (",
"      <a class=\"graphic graphic_figure graphicRef79779 \" href=\"UTD.htm?40/9/41106\">",
"       figure 3",
"      </a>",
"      ). The airway is inserted into the oropharynx after induction of general anesthesia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=see_link&amp;anchor=H8#H8\">",
"       \"Devices for difficult emergency airway management in adults\", section on 'Laryngeal mask airways'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Complications associated with LMA placement include sore throat and oropharyngeal trauma. It should also be noted that the LMA is a supraglottic airway that does not prevent aspiration pneumonitis. An incidence of aspiration of 2 in 10,000 patients receiving anesthesia with an LMA has been cited, although the authors do note that these devices should be used with caution in patients with increased risk factors for aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Brain monitoring",
"      </strong>",
"      &ndash; Awareness with recall describes intraoperative consciousness and recall of intraoperative events and is potentially psychologically devastating complication. Monitoring strategies are aimed at recognizing when the administered level of anesthesia is insufficient and may include the use a brain monitor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34504?source=see_link&amp;anchor=H13#H13\">",
"       \"Awareness with recall following general anesthesia\", section on 'Depth of anesthesia monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Peripheral intravenous catheter placement",
"      </strong>",
"      &ndash; The vast majority of patients undergoing anesthesia have a peripheral venous cannula placed for administration of medications, intravenous fluids, and blood products. Veins of the upper limbs and hand are the most common cannulation sites used by the anesthesiologist. The use of local anesthetic prior to placement reduces pain associated with cannulation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/45\">",
"       45",
"      </a>",
"      ]. The most frequent early complications are thrombophlebitis and extravasation. Catheter infection is a complication that is most likely to occur after more than three to four days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=see_link\">",
"       \"Peripheral venous access in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Central venous catheter insertion",
"      </strong>",
"      &ndash; Placement of a catheter into a central vein (subclavian, jugular) may be helpful for both monitoring volume status and for the infusion of vasoactive or medications too irritating for peripheral administration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"       \"Overview of central venous access\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42729?source=see_link\">",
"       \"Intraoperative fluid management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Arterial catheter insertion",
"      </strong>",
"      &ndash; Arterial catheters may be placed by anesthesiologists for continuous blood pressure monitoring or frequent blood gas analysis (evaluating respiratory and metabolic function). Arterial catheters are typically placed in the radial artery at the level of the wrist using a Seldinger technique. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=see_link\">",
"       \"Arterial catheterization techniques for invasive monitoring\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"       \"Arterial blood gases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary artery catheterization",
"      </strong>",
"      &ndash; Pulmonary artery catheterization involves the placement of a catheter under hemodynamic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluoroscopic guidance through the central venous circulation, the right atrium, right ventricle, and into the pulmonary artery. Under ideal circumstances, this catheter provides significant hemodynamic information to the practitioner including cardiac output, pulmonary artery pressure, pulmonary vascular resistance, and pulmonary artery occlusion pressure (reflecting left ventricular end diastolic pressures). There is insufficient evidence to support the routine use of pulmonary artery catheterization for high risk patients undergoing noncardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19817/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"       \"Pulmonary artery catheterization: Indications and complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=see_link\">",
"       \"Insertion of pulmonary artery catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Transesophageal echocardiography",
"      </strong>",
"      &ndash; Goal-directed physiologic management using imaging technology (transesophageal echocardiography) is gaining traction in the anesthesia community in an effort to ensure optimal outcomes for high-risk procedures, particularly in cardiac anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=see_link\">",
"       \"Patient information: Anesthesia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of anesthesia is to provide the desired combination of analgesia, amnesia, and optimal operating conditions while ensuring physiologic homeostasis. Careful assessment of the patient preoperatively and consideration of anesthetic choices will improve the operative outcome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The types of anesthesia include general anesthesia, neuraxial anesthesia (spinal and epidural), peripheral nerve blocks, monitored anesthetic care (including deep sedation), and light or moderate sedation. ASA standards and guidelines are available",
"      <a class=\"external\" href=\"file://www.asahq.org/For-Members/Standards-Guidelines-and-Statements.aspx\">",
"       online",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multimodal analgesia may be used to decrease opioid side effects. This may include utilizing a combined technique (ie, general anesthesia plus epidural or peripheral nerve block analgesia) or the addition of non-opioid analgesics into the perioperative analgesic plan. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Types of anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The proper choice of anesthetic depends on the planned procedure and the patient's overall health and medical problems. The American Society of Anesthesiologists (ASA) classification system is helpful for stratifying the risks of anesthesia through assessment of the patient's underlying medical problems. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Risk classification systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of anesthetic vapors and intravenous agents requires airway access, venous access, and sometimes special monitoring devices such as arterial, central venous, or pulmonary artery catheters, or transesophageal echocardiography. The use of these devices depends on the planned procedure and the patient's medical risk. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Common anesthesia procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/1\">",
"      Pollard RJ, Coyle JP, Gilbert RL, Beck JE. Intraoperative awareness in a regional medical system: a review of 3 years' data. Anesthesiology 2007; 106:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/2\">",
"      Ranta SO, Laurila R, Saario J, et al. Awareness with recall during general anesthesia: incidence and risk factors. Anesth Analg 1998; 86:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/3\">",
"      Rungreungvanich M, Thienthong S, Charuluxananan S, et al. Predictors of intra-operative recall of awareness: Thai Anesthesia Incidents Study (THAI Study): a case-control study. J Med Assoc Thai 2007; 90:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/4\">",
"      Jayr C, Thomas H, Rey A, et al. Postoperative pulmonary complications. Epidural analgesia using bupivacaine and opioids versus parenteral opioids. Anesthesiology 1993; 78:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/5\">",
"      White PF, Kehlet H, Neal JM, et al. The role of the anesthesiologist in fast-track surgery: from multimodal analgesia to perioperative medical care. Anesth Analg 2007; 104:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/6\">",
"      Myles PS, Hendrata M, Bennett AM, et al. Postoperative nausea and vomiting. Propofol or thiopentone: does choice of induction agent affect outcome? Anaesth Intensive Care 1996; 24:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/7\">",
"      Hug CC Jr, McLeskey CH, Nahrwold ML, et al. Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg 1993; 77:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/8\">",
"      Lundy JB, Slane ML, Frizzi JD. Acute adrenal insufficiency after a single dose of etomidate. J Intensive Care Med 2007; 22:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/9\">",
"      Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989; 36:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/10\">",
"      Bunker JP. Final Report of the National Halothane Study. Anesthesiology 1968; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/11\">",
"      Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology 2008; 109:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/12\">",
"      Flippo TS, Holder WD Jr. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. Arch Surg 1993; 128:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/13\">",
"      Baum VC. When nitrous oxide is no laughing matter: nitrous oxide and pediatric anesthesia. Paediatr Anaesth 2007; 17:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/14\">",
"      R&ouml;hm KD, Piper SN, Suttner S, et al. Early recovery, cognitive function and costs of a desflurane inhalational vs. a total intravenous anaesthesia regimen in long-term surgery. Acta Anaesthesiol Scand 2006; 50:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/15\">",
"      Maurer SG, Chen AL, Hiebert R, et al. Comparison of outcomes of using spinal versus general anesthesia in total hip arthroplasty. Am J Orthop (Belle Mead NJ) 2007; 36:E101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/16\">",
"      McKenzie PJ, Wishart HY, Gray I, Smith G. Effects of anaesthetic technique on deep vein thrombosis. A comparison of subarachnoid and general anaesthesia. Br J Anaesth 1985; 57:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/17\">",
"      Naesh O, Hindberg I, Friis J, Christiansen C. General versus regional anaesthesia and platelet aggregation in minor surgery. Eur J Anaesthesiol 1994; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/18\">",
"      Parker SD, Breslow MJ, Frank SM, et al. Catecholamine and cortisol responses to lower extremity revascularization: correlation with outcome variables. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Crit Care Med 1995; 23:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/19\">",
"      Park WY, Thompson JS, Lee KK. Effect of epidural anesthesia and analgesia on perioperative outcome: a randomized, controlled Veterans Affairs cooperative study. Ann Surg 2001; 234:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/20\">",
"      Stride PC, Cooper GM. Dural taps revisited. A 20-year survey from Birmingham Maternity Hospital. Anaesthesia 1993; 48:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/21\">",
"      Vallejo MC, Mandell GL, Sabo DP, Ramanathan S. Postdural puncture headache: a randomized comparison of five spinal needles in obstetric patients. Anesth Analg 2000; 91:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/22\">",
"      Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/23\">",
"      Horlocker TT, Wedel DJ, Schroeder DR, et al. Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia. Anesth Analg 1995; 80:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/24\">",
"      Litz RJ, Gottschlich B, Stehr SN. Spinal epidural hematoma after spinal anesthesia in a patient treated with clopidogrel and enoxaparin. Anesthesiology 2004; 101:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/25\">",
"      Tam NL, Pac-Soo C, Pretorius PM. Epidural haematoma after a combined spinal-epidural anaesthetic in a patient treated with clopidogrel and dalteparin. Br J Anaesth 2006; 96:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/26\">",
"      Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/27\">",
"      Wiegel M, Gottschaldt U, Hennebach R, et al. Complications and adverse effects associated with continuous peripheral nerve blocks in orthopedic patients. Anesth Analg 2007; 104:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/28\">",
"      van Zundert A, Helmst&auml;dter A, Goerig M, Mortier E. Centennial of intravenous regional anesthesia. Bier's Block (1908-2008). Reg Anesth Pain Med 2008; 33:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/29\">",
"      Guay J. Adverse events associated with intravenous regional anesthesia (Bier block): a systematic review of complications. J Clin Anesth 2009; 21:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/30\">",
"      Brown EM, McGriff JT, Malinowski RW. Intravenous regional anaesthesia (Bier block): review of 20 years' experience. Can J Anaesth 1989; 36:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/31\">",
"      American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002; 96:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/32\">",
"      Bhananker SM, Posner KL, Cheney FW, et al. Injury and liability associated with monitored anesthesia care: a closed claims analysis. Anesthesiology 2006; 104:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/33\">",
"      Botney R. Improving patient safety in anesthesia: a success story? Int J Radiat Oncol Biol Phys 2008; 71:S182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/34\">",
"      Fleisher LA, Pasternak LR, Herbert R, Anderson GF. Inpatient hospital admission and death after outpatient surgery in elderly patients: importance of patient and system characteristics and location of care. Arch Surg 2004; 139:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/35\">",
"      Cohen MM, Duncan PG, Tate RB. Does anesthesia contribute to operative mortality? JAMA 1988; 260:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/36\">",
"      Lanier WL. A three-decade perspective on anesthesia safety. Am Surg 2006; 72:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/37\">",
"      Wolters U, Wolf T, St&uuml;tzer H, Schr&ouml;der T. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996; 77:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/38\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/39\">",
"      Rose DK, Cohen MM. The airway: problems and predictions in 18,500 patients. Can J Anaesth 1994; 41:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/40\">",
"      Burkle CM, Walsh MT, Harrison BA, et al. Airway management after failure to intubate by direct laryngoscopy: outcomes in a large teaching hospital. Can J Anaesth 2005; 52:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/41\">",
"      Biro P, Seifert B, Pasch T. Complaints of sore throat after tracheal intubation: a prospective evaluation. Eur J Anaesthesiol 2005; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/42\">",
"      Charuluxananan S, Punjasawadwong Y, Suraseranivongse S, et al. The Thai Anesthesia Incidents Study (THAI Study) of anesthetic outcomes: II. Anesthetic profiles and adverse events. J Med Assoc Thai 2005; 88 Suppl 7:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/43\">",
"      Suraseranivongse S, Valairucha S, Chanchayanon T, et al. The Thai Anesthesia Incidents Study (THAI Study) of pulmonary aspiration: a qualitative analysis. J Med Assoc Thai 2005; 88 Suppl 7:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/44\">",
"      Brimacombe JR, Berry A. The incidence of aspiration associated with the laryngeal mask airway: a meta-analysis of published literature. J Clin Anesth 1995; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/45\">",
"      Nuttall GA, Barnett MR, Smith RL 2nd, et al. Establishing intravenous access: a study of local anesthetic efficacy. Anesth Analg 1993; 77:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/46\">",
"      Harvey S, Young D, Brampton W, et al. Pulmonary artery catheters for adult patients in intensive care. Cochrane Database Syst Rev 2006; :CD003408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/47\">",
"      Polanczyk CA, Rohde LE, Goldman L, et al. Right heart catheterization and cardiac complications in patients undergoing noncardiac surgery: an observational study. JAMA 2001; 286:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19817/abstract/48\">",
"      Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 399 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19817=[""].join("\n");
var outline_f19_22_19817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Amnesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuromuscular blockade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TYPES OF ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Maintenance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Emergence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuraxial anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Spinal anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Epidural anesthesia and analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Peripheral nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3483410\">",
"      Intravenous regional block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monitored anesthesia care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREOPERATIVE RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Risk classification systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMMON ANESTHESIA PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/399|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/54/42863\" title=\"figure 1\">",
"      Placement of endotracheal tube anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/0/28676\" title=\"figure 2\">",
"      Endotracheal intubation lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/9/41106\" title=\"figure 3\">",
"      Laryngeal mask airway position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/24/30092\" title=\"table 1\">",
"      Local anesthetics used for regional anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8733\" title=\"table 2\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34504?source=related_link\">",
"      Awareness with recall following general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=related_link\">",
"      Insertion of pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42729?source=related_link\">",
"      Intraoperative fluid management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37574?source=related_link\">",
"      Neuraxial analgesia and anesthesia for labor and delivery: Options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=related_link\">",
"      Patient information: Anesthesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=related_link\">",
"      Peripheral venous access in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_22_19818="Natriuretic peptide measurement in heart failure";
var content_f19_22_19818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natriuretic peptide measurement in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Horng H Chen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/22/19818/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/22/19818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natriuretic peptide system impacts salt and water handling and pressure regulation and may influence myocardial structure and function.",
"   </p>",
"   <p>",
"    Brain natriuretic peptide (BNP) is a natriuretic hormone initially identified in the brain but released primarily from the heart, particularly the ventricles. Cleavage of the prohormone proBNP produces biologically active 32 amino acid BNP as well as biologically inert 76 amino acid N-terminal pro-BNP (NT-proBNP).",
"   </p>",
"   <p>",
"    Atrial natriuretic peptide (ANP) is a hormone that is released from myocardial cells in the atria and in some cases the ventricles in response to volume expansion and possibly increased wall stress [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/1\">",
"     1",
"    </a>",
"    ]. ANP circulates primarily as a 28 amino acid polypeptide, consisting of amino acids 99-126 from the C-terminal end of its prohormone, pro-ANP.",
"   </p>",
"   <p>",
"    The release of both ANP and BNP is increased in heart failure (HF), as ventricular cells are recruited to secrete both ANP and BNP in response to the high ventricular filling pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/2\">",
"     2",
"    </a>",
"    ]. The plasma concentrations of both hormones are increased in patients with asymptomatic and symptomatic left ventricular dysfunction, permitting their use in diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef55557 \" href=\"UTD.htm?20/13/20701\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnostic and prognostic value of measuring plasma BNP, N-terminal pro-BNP (NT-proBNP) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in patients with heart failure will be presented here.",
"   </p>",
"   <p>",
"    Natriuretic levels in non-heart failure settings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29573?source=see_link\">",
"     \"Natriuretic peptide measurement in non-heart failure settings\"",
"    </a>",
"    .) The possible therapeutic role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    (recombinant human BNP) in the management of patients with decompensated HF is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=see_link\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC ROLE IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ANP and BNP have diuretic, natriuretic, and hypotensive effects. They also inhibit the renin-angiotensin system, endothelin secretion, and systemic and renal sympathetic activity (",
"    <a class=\"graphic graphic_figure graphicRef64943 \" href=\"UTD.htm?5/60/6094\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/3\">",
"     3",
"    </a>",
"    ]. Among patients with HF, increased secretion of ANP and BNP may partially counteract the effects of norepinephrine, endothelin, and angiotensin II, limiting the degree of vasoconstriction and sodium retention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one study of patients with moderately severe HF, for example, administration of an orally active inhibitor of the endopeptidase that degrades ANP led to reductions in plasma aldosterone concentrations and right ventricular (RV) and left ventricular (LV) filling pressures, as well as a decrease in body weight presumed to be due to diuresis, natriuresis, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/4\">",
"     4",
"    </a>",
"    ]. These effects were presumably mediated by enhanced natriuretic peptide activity.",
"   </p>",
"   <p>",
"    An unexpected finding is that BNP may protect against collagen accumulation and the pathologic remodeling that contributes to progressive HF. Studies in BNP knockout mice reveal increased cardiac fibrosis in response to ventricular pressure overload [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link\">",
"     \"Cardiac remodeling: Basic aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSAY INTERPRETATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Plasma BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of clinical immunoassays are clinically available for plasma BNP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/7\">",
"     7",
"    </a>",
"    ]. These include a rapid point-of-care assay [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/8-11\">",
"     8-11",
"    </a>",
"    ] as well as central lab assays that offer improved precision compared to the point-of-care test. These assays are harmonized at a value of 100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    but above or below this level, the correlations are not strong. &nbsp;",
"   </p>",
"   <p>",
"    Plasma BNP concentrations have been variously reported in units of",
"    <span class=\"nowrap\">",
"     pmol/L,",
"    </span>",
"    <span class=\"nowrap\">",
"     ng/L,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    The currently available rapid assay reports results in",
"    <span class=\"nowrap\">",
"     pg/mL;",
"    </span>",
"    the assay range is 5 to 1300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/11\">",
"     11",
"    </a>",
"    ] or 1.4 to 376",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic factors may account for roughly 40 percent of the total variation in plasma BNP in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/12\">",
"     12",
"    </a>",
"    ]. Similar variability has been noted with N-terminal pro-BNP (NT-proBNP) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'N-terminal pro-BNP'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A potential source of error is that plasma BNP concentrations can vary with the assay used (due to various antibody configurations), age, sex, and body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/14\">",
"     14",
"    </a>",
"    ]. The normal values tend to increase with age and to be higher in women than men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Plasma N-terminal pro-BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, the plasma concentrations of BNP and NT-proBNP are similar (approximately 10",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    However, in patients with LV dysfunction, plasma NT-proBNP rises more than BNP. Scaling varies among BNP assays while NT-proBNP assays are standardized, so there is no simple conversion factor to compare BNP and NT-proBNP levels. As discussed below, an NT-proBNP level &gt;900",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    provides roughly equivalent accuracy as a BNP level of &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    for diagnosis of heart failure.",
"   </p>",
"   <p>",
"    Plasma concentrations of NT-proBNP are higher in older individuals and in women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/13\">",
"     13",
"    </a>",
"    ]. On the other hand, plasma BNP and NT-proBNP are lower in obese individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/15\">",
"     15",
"    </a>",
"    ], indicating that optimal reference intervals should account for age, gender, and perhaps body mass index (or other measure of body composition). In addition, NT-proBNP increases with renal failure and optimal cut-off values for diagnosis in such patients have not been clearly established [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22200902\">",
"     'Renal failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Assay purity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available commercial assays for plasma BNP or NT-proBNP actually measure mixtures of peptides. Plasma BNP assays appear to detect various degradation products of BNP as well as proBNP. Assays for NT-proBNP likely also detect proBNP. The relative contribution of individual natriuretic peptides has not yet been elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variability in peptide measurements must be considered when interpreting serial BNP or NT-proBNP results. Intraindividual biologic variation as well as analytic assay variation contribute to total variation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/17\">",
"     17",
"    </a>",
"    ]. Manual and point-of-care assays have greater analytic variation than central laboratory analyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/18\">",
"     18",
"    </a>",
"    ]. Total variability determines the percentage change (the relative change value or RCV) needed to demonstrate a significant difference in results over time. In a review of studies of BNP and NT-proBNP variability, a mean 25 percent decrease in BNP was required for a significant within day change and a mean 72 percent decline in BNP was required for a significant week to week change [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/18\">",
"     18",
"    </a>",
"    ]. Variability for NT-proBNP testing was less, so RCVs were lower: an 11 percent decrease was required for a significant within day change and a 47 percent decrease was required for a significant week to week change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201902\">",
"    <span class=\"h2\">",
"     Impact of other conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22200902\">",
"    <span class=\"h3\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP and NT-proBNP concentrations are elevated in patients with renal failure. In patients with chronic kidney disease, decreased estimated GFR is associated with increased plasma BNP and even greater elevation in NT-proBNP concentrations.",
"   </p>",
"   <p>",
"    Plasma BNP concentrations are often elevated in patients with renal insufficiency, whether or not they have clinically diagnosed HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. BNP is cleared by the receptor-mediated binding and removal, neutral endopeptidase [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], as well as by passive excretion so GFR is inversely related to BNP concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. As a result, the cut-off values for plasma BNP in patients with renal insufficiency are different from those in patients with normal renal function. Elevations in BNP levels in renal failure may also result from volume expansion renal or from left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/19\">",
"     19",
"    </a>",
"    ] and monitoring plasma BNP does not appear to facilitate the management of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not use plasma BNP for the diagnosis or management of HF in patients with renal failure, with or without dialysis. The main value would be a low plasma BNP, which would exclude left ventricular dysfunction.",
"   </p>",
"   <p>",
"    Measuring plasma NT-proBNP has an added problem since NT-proBNP is cleared by the kidney and its plasma concentration is elevated by renal failure alone. There are insufficient data to establish clear cut-off values for NT-proBNP in this setting. In a review of 599 patients with a serum creatinine &le;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    who presented to the Emergency Department with a complaint of dyspnea, cut-off values for patients with an estimated glomerular filtration rate (GFR) of &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    were &gt;450",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in those less than 50 years of age and &gt;900",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in older patients; the cutoff was 1200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    for patients with a GFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/16\">",
"     16",
"    </a>",
"    ]. Using these values, the sensitivity and specificity for diagnosing HF were 85 and 88 percent for those with a GFR &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and 89 and 72 percent in those with a GFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27939917\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese patients tend to have lower plasma BNP and NT-proBNP concentrations than nonobese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/15,24-27\">",
"     15,24-27",
"    </a>",
"    ]. There are conflicting data as to whether the lower values in obese patients reflect a direct association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/15\">",
"     15",
"    </a>",
"    ] or are a function of other variables including age, sex, and HF severity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/26\">",
"     26",
"    </a>",
"    ]. Despite the lower values with obesity, higher plasma BNP values within any body mass index category is associated with worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201975\">",
"    <span class=\"h3\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natriuretic peptide levels are elevated in some patients with non-heart failure conditions such as coronary heart disease, valvular heart disease, pulmonary hypertension, and sepsis. The diagnostic and prognostic value of measuring plasma BNP and N-terminal pro-BNP (NT-proBNP) in asymptomatic individuals and patients with non-heart failure conditions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29573?source=see_link\">",
"     \"Natriuretic peptide measurement in non-heart failure settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PLASMA BNP IN HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circulating concentration of BNP is less than 20 percent of that of ANP in normal subjects, but can equal or exceed that of ANP in patients with HF; this wider range of concentrations makes measurement of BNP more useful than ANP in evaluation of patients with HF. For this reason, the clinical experience with plasma BNP is much greater than with plasma ANP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The plasma half-life of BNP is estimated to be about 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/30\">",
"     30",
"    </a>",
"    ]. However, as noted above, assays for BNP likely measure a mixture of BNP and proBNP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     BNP and the diagnosis of HF in the patient with dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing HF as a cause of dyspnea in patients presenting to the emergency department is extremely important, but symptoms and physical findings may not be sufficiently sensitive to make an accurate diagnosis. The assay for plasma BNP is a useful test in the evaluation of patients with dyspnea, and is especially useful as a component of the evaluation of suspected HF when the diagnosis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/31-37\">",
"     31-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'BNP and NT-proBNP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Breathing Not Properly study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of rapid bedside measurement of plasma BNP for distinguishing between HF and a pulmonary cause of dyspnea was best evaluated in the Breathing Not Properly (BNP) study of 1586 patients presenting to the emergency department or urgent care setting with a major complaint of acute dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/31\">",
"     31",
"    </a>",
"    ]. The final diagnosis was HF in 47 percent (confirmed by chest x-ray",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    echocardiography and other clinical tests by two independent cardiologists), no HF in 49 percent, and noncardiac dyspnea in patients with a past history of LV dysfunction in 5 percent. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma BNP was markedly higher in patients with clinically diagnosed HF (including patients with right heart failure due to cor pulmonale) compared to those without HF (mean 675 versus 110",
"      <span class=\"nowrap\">",
"       pg/mL).",
"      </span>",
"      Intermediate values were found in patients with baseline LV dysfunction without an acute exacerbation (346",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef82685 \" href=\"UTD.htm?39/28/40397\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A plasma BNP &gt;100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      diagnosed HF with a sensitivity, specificity, and predictive accuracy of 90, 76, and 83 percent, respectively. Choosing values &gt;125 or &gt;150",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      decreased sensitivity, increased specificity, and did not change overall predictive accuracy. The predictive accuracy of plasma BNP for HF was equivalent to or better than other parameters such as cardiomegaly on chest x-ray, a history of HF, or rales on physical examination, and was better than the widely used NHANES and Framingham criteria for the diagnosis of HF (83 versus 67 and 73 percent, respectively). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent analysis showed that atrial fibrillation (AF), which was present in 292 patients, was associated with higher BNP levels in the patients who did not have a final diagnosis of HF (119 versus 25",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in patients without AF) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/38\">",
"     38",
"    </a>",
"    ]. As a result, a BNP cutoff of &ge;100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    was associated with a specificity of only 40 percent compared to 79 percent in patients without AF. Using a cutoff of &ge;200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in patients with AF increased specificity from 40 to 73 percent with a smaller reduction in sensitivity from 95 to 85 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The plasma concentration of BNP correlated with NYHA functional class, ranging from 244 to 817",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      for class I to IV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report from the BNP study compared plasma BNP to initial clinical judgment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/32\">",
"     32",
"    </a>",
"    ]. Among patients judged clinically to have a &ge;80 percent probability of HF, a plasma BNP &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    was more sensitive (90 versus 49 percent) but less specific (73 versus 96 percent) than clinical judgment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/32\">",
"     32",
"    </a>",
"    ]. Adding BNP to clinical judgment increased diagnostic accuracy (HF versus no HF) from 74 to 81 percent. Among patients with a 21 to 79 percent clinical probability of HF, a plasma BNP &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    had a diagnostic accuracy of 74 percent and only misclassified 7 percent of patients who had HF. Among patients originally thought to have less than a 21 percent clinical probability of HF, 17 percent had a final diagnosis of HF and plasma BNP correctly diagnosed 90 percent of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in plasma BNP can establish the presence of HF due to diastolic dysfunction with similar accuracy to systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/34,39,40\">",
"     34,39,40",
"    </a>",
"    ]. However, the values do not differentiate between systolic and diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/34,39\">",
"     34,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Impact on outcomes and costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the impact on health outcomes and health services utilization of BNP measurement for evaluation of dyspnea have reported conflicting results which may be due to differences in patient populations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    health systems (eg, high clinical diagnostic accuracy without BNP testing may be associated with less benefit with BNP testing).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Swiss trial, 452 patients who presented to an emergency department with acute dyspnea were randomly assigned to a diagnostic strategy with or without the use of plasma BNP measurement [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/41\">",
"       41",
"      </a>",
"      ]. Significantly fewer patients in the BNP group than the control group were hospitalized (75 versus 85 percent) or admitted to the intensive care unit (15 versus 24 percent). The median length of stay was significantly shorter in the BNP group (8 versus 11 days) and the cost of treatment was significantly less ($5410 versus $7264). Both clinical improvements and lower costs were still present in a 180 day follow-up study [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"       \"A short primer on cost-effectiveness analysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an Australian trial, 612 patients presenting with acute dyspnea were randomly assigned to have BNP tested or not tested [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/43\">",
"       43",
"      </a>",
"      ]. There were no differences between the BNP and control group in hospitalization rate (86 versus 87 percent) or length of stay (4.4 versus 5 days) or management in the emergency department.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Discordance between BNP and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with symptomatic HF have high plasma BNP concentrations and not all asymptomatic patients have low values. This was demonstrated in a review of 558 consecutive ambulatory patients with treated stable HF in a specialized outpatient HF clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/44\">",
"     44",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 449 symptomatic patients, 106 (24 percent) had plasma BNP &lt;100",
"      <span class=\"nowrap\">",
"       pg/mL.",
"      </span>",
"      These patients were more likely to be young and female and to have a nonischemic cardiomyopathy.",
"     </li>",
"     <li>",
"      On the other hand, elevated plasma BNP was seen in some of the 109 asymptomatic patients. Although the mean plasma BNP in this group was 87",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      values as high as 572",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      were seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings illustrate the importance of the range of individual patient variation, as with any diagnostic test. The use of serial serum BNP concentrations to monitor the clinical course of a patient provides a more reliable guide to management than can be obtained from a single measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prognosis of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP levels have been evaluated as predictors of outcome in both acute and chronic HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Chronic HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP provides prognostic information in patients with chronic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/45-49\">",
"     45-49",
"    </a>",
"    ], and those with asymptomatic or minimally symptomatic LV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review analyzed 19 studies in which plasma BNP was used to estimate the relative risk of death or cardiovascular events in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/54\">",
"     54",
"    </a>",
"    ]. Every 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    increase in plasma BNP was associated with a 35 percent increase in the relative risk of death. In multivariable models, plasma BNP was a strong indicator of risk and may be a better predictor of survival than traditional risk factors such as NYHA class and possibly left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    In an analysis of more than 4000 patients from the Val-HeFT trial, those with a baseline plasma BNP concentration in the highest quartile (&ge;238",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    had a significantly greater mortality at two years than those with a plasma BNP in the lowest quartile (&lt;41",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    (32.4 versus 9.7 percent) (",
"    <a class=\"graphic graphic_figure graphicRef78693 \" href=\"UTD.htm?35/56/36750\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, persistent elevation of plasma BNP despite optimal medical therapy also has prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/49,50,52,55,56\">",
"     49,50,52,55,56",
"    </a>",
"    ]. In one series of 85 chronic HF patients, a plasma BNP below 73",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    was associated with markedly and significantly higher survival compared to those with higher values (",
"    <a class=\"graphic graphic_figure graphicRef66458 \" href=\"UTD.htm?16/44/17101\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/52\">",
"     52",
"    </a>",
"    ]. In another series of 102 patients with class III and IV HF, a plasma BNP concentration persistently above 240",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    after treatment had a sensitivity and specificity of 73 and 74 percent for mortality at follow-up of more than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/50\">",
"     50",
"    </a>",
"    ]. In hospitalized patients, persistent elevation of plasma BNP prior to discharge from the hospital is predictive of death or readmission [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, plasma BNP and N-terminal pro-BNP concentrations tend to be lower in obese and overweight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/15,24-27\">",
"     15,24-27",
"    </a>",
"    ]. Despite the relatively lower values, plasma BNP retains its prognostic value in such patients with advanced heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Acute decompensated HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between admission plasma BNP levels and the risk of in-hospital mortality for patients with acute decompensated HF was assessed in the ADHERE registry [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/57\">",
"     57",
"    </a>",
"    ]. Admission BNP levels were available in 19,544 patients with HF due to systolic dysfunction and in 18,164 HF patients with preserved LV function. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BNP values were categorized according to quartiles. Quartiles 1 to 4: &lt;430, 430 to 839, 840 to 1729, and &ge;1739",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      There was a nearly linear relationship between BNP quartiles and in-hospital mortality. Quartiles 1 to 4: 1.9, 2.8, 3.8, and 6 percent respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Screening for LV dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP has been evaluated as a screening test for asymptomatic LV dysfunction, with the goal being early identification so that therapy can be given to slow the progression to overt HF. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=see_link\">",
"     \"Screening for asymptomatic left ventricular dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Major society recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines note that measurement of natriuretic peptide levels (BNP and NT-proBNP) can be useful in the evaluation and risk stratification of patients presenting in the urgent care setting in whom the clinical diagnosis of HF is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/58\">",
"     58",
"    </a>",
"    ]. These measurements are to be viewed as part of the total evaluation but should not be used in isolation to confirm or exclude the presence of HF.",
"   </p>",
"   <p>",
"    The 2006 Heart Failure Society of America (HFSA) guidelines recommend that BNP or NT-proBNP levels be assessed in all patients suspected of having HF when the diagnosis is not certain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/59\">",
"     59",
"    </a>",
"    ]. The 2008 European Society of Cardiology (ESC) guidelines also include BNP and NT-proBNP among the diagnostic tests that are useful in patients with suspected HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of BNP in differentiating cardiac and noncardiac causes of dyspnea in difficult to assess patients remains uncertain. Plasma BNP concentration may be useful in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a part of the clinical evaluation of patients presenting with dyspnea of uncertain etiology, including patients with a history of cardiomyopathy and HF who may have a noncardiac cause of dyspnea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most dyspneic patients with HF have values above 400",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    while values below 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    have a very high negative predictive value for HF as a cause of dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/28\">",
"     28",
"    </a>",
"    ]. In the range between 100 and 400",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    plasma BNP concentrations are not very sensitive or specific for detecting or excluding HF. Other diagnoses, such as pulmonary embolism, LV dysfunction without exacerbation, and cor pulmonale should also be considered in patients with plasma BNP concentrations in this range.",
"   </p>",
"   <p>",
"    Normal plasma BNP values increase with age and are higher in women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, somewhat higher cutoff values may be needed in these settings, although the optimal discriminatory values that should be used have not been determined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possibly, to monitor patients with an established diagnosis of HF, especially those with moderate to severe HF. Such measurements can be made as an adjunct to outpatient follow-up office visits. A rise in plasma BNP above the patient's own baseline value should trigger closer assessment for a possible exacerbation of HF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several important limitations to the use of plasma BNP for diagnosis and follow-up of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients may present with more than one cause of dyspnea (such as pneumonia and an exacerbation of HF). Thus, a high plasma BNP concentration does not exclude the presence of other diseases.",
"     </li>",
"     <li>",
"      In some patients with acute decompensated HF, plasma BNP levels are not diagnostic.",
"     </li>",
"     <li>",
"      Some patients with severe chronic HF may have persistently elevated plasma BNP concentrations regardless of treatment, and such levels may not be useful in guiding management.",
"     </li>",
"     <li>",
"      Right heart failure and pulmonary hypertension are associated with elevations in plasma BNP (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29573?source=see_link&amp;anchor=H27657061#H27657061\">",
"       \"Natriuretic peptide measurement in non-heart failure settings\", section on 'Pulmonary hypertension'",
"      </a>",
"      ). However, when right heart failure is due solely to lung disease and not due to secondary pulmonary hypertension from left sided heart disease or as part of a global cardiomyopathy, elevated plasma BNP may be misinterpreted since dyspnea in these patients is due to lung disease not left heart failure.",
"     </li>",
"     <li>",
"      Plasma BNP measurements alone are not sufficient to guide therapeutic decision-making in patients with HF. They should be used as an adjunct to, and not a substitute for, clinical assessment. As an example, failure of plasma BNP to change significantly should not be interpreted as conclusive evidence that the new therapy was of no benefit.",
"     </li>",
"     <li>",
"      Plasma BNP cannot be used for clinical assessment in patients being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      ; in comparison, N-terminal pro-BNP can be used. (See",
"      <a class=\"local\" href=\"#H27658361\">",
"       'Measurement during treatment with nesiritide'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     N-TERMINAL PRO-BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like ANP, BNP is cleaved from the C-terminal end of its prohormone, pro-BNP. The N-terminal fragment, N-terminal pro-BNP (NT-proBNP), is also released into the circulation. NT-proBNP has a longer plasma half-life than BNP (approximately 25 to 70 versus 20 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/30\">",
"     30",
"    </a>",
"    ]. However, as noted above, assays for NT-proBNP likely measure a mixture of NT-proBNP and proBNP. Issues related to the NT-proBNP assay are discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Assay interpretation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Measurement of NT-proBNP, like measurement of plasma BNP, has diagnostic and prognostic value in heart failure and other cardiovascular diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Role in HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of diagnosis of HF in both primary care and emergency department settings can be improved with NT-proBNP measurement. The following observations illustrate the utility of NT-proBNP primarily in patients with systolic HF; preliminary data suggest it is also useful in HF due to diastolic dysfunction as is plasma BNP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diastolic dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Acute decompensated HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like BNP, NT-proBNP has been found to be useful in the evaluation of a patient presenting with dyspnea in the acute setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/31,32,62-66\">",
"     31,32,62-66",
"    </a>",
"    ]. This is best illustrated by a retrospective cohort study that combined and analyzed data from three previous prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/62\">",
"     62",
"    </a>",
"    ]. Differences in plasma NT-proBNP among 1256 patients with and without acute heart failure were compared, and the relationship between plasma NT-proBNP and symptoms was examined. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal value for distinguishing HF from other causes of dyspnea varied with patient age. For patients &lt;50, 50 to 75, and &gt;75 years of age, the optimal plasma NT-proBNP cutoffs for diagnosing HF were 450",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      900",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      and 1800",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      respectively. Overall, these cutoffs yielded a sensitivity and specificity of 90 and 84 percent, respectively.",
"     </li>",
"     <li>",
"      Across the entire population, NT-proBNP levels below 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      were optimal for excluding a diagnosis of HF, with a negative predictive value of 98 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The concentration of NT-proBNP is elevated in the pleural fluid in patients with HF and a pleural effusion and may therefore be of some value in the diagnosis of pleural effusion. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\", section on 'N-terminal pro-BNP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cost effectiveness &mdash; Use of NT-proBNP to guide diagnostic assessment of dyspnea in the emergency department may result in cost savings as well as improved clinical outcomes. This potential benefit was evaluated in the IMPROVE-CHF study of 500 patients presenting to emergency departments with dyspnea who were randomly assigned to usual care alone or with inclusion of guidance by NT-proBNP [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/67\">",
"       67",
"      </a>",
"      ]. Adding NT-proBNP to clinical judgment enhanced the accuracy of diagnosis, reduced the duration of the emergency department visits (5.6 versus 6.3 hours), the number of patients rehospitalized over 60 days (13 versus 20 percent), and direct medical costs of all emergency department visits, hospitalizations, and subsequent outpatient services (US $5180 versus $6129 per patient).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma NT-proBNP correlates with prognosis in patients with acute and chronic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/51,66,68-71\">",
"     51,66,68-71",
"    </a>",
"    ]. In a subgroup of 1011 patients in the COPERNICUS study, the median baseline NT-proBNP concentration was 1767",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/68\">",
"     68",
"    </a>",
"    ]. All-cause mortality at one year was significantly higher for patients with a plasma NT-proBNP above the median, compared to levels below the median (22 versus 7 percent, risk ratio 2.7). A similar increase was found in the combined end point of all-cause mortality or hospitalization for HF (38 versus 19 percent, risk ratio 2.4). Similar observations were made in the",
"    <span class=\"nowrap\">",
"     Australia/New",
"    </span>",
"    Zealand Heart Failure trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/51,69\">",
"     51,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Primary care setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of NT-proBNP in the primary care setting was demonstrated in a study of 305 patients presenting to their general practitioner with symptoms of HF who were initially evaluated and then randomly assigned to a second diagnostic evaluation with or without knowledge of the result [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/72\">",
"     72",
"    </a>",
"    ]. Final diagnoses were made by an expert panel. Diagnostic accuracy (either correct identification or exclusion of HF) improved from 52 to 60 percent without NT-proBNP (8 percent change) but from 49 to 70 percent with NT-proBNP (21 percent change).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Role in cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-terminal pro-BNP predicts cardiac involvement and prognosis in patients with AL amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/73\">",
"     73",
"    </a>",
"    ] and may be a useful screen for left ventricular dysfunction due to late cardiotoxicity in children who have received anthracycline chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link&amp;anchor=H27261444#H27261444\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\", section on 'BNP and N-terminal pro-BNP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H33#H33\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Brain natriuretic peptide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     COMPARISON OF PLASMA BNP AND N-TERMINAL PRO-BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available comparing the diagnostic and prognostic values of plasma BNP and NT-pro-BNP. As noted above, there is no universal conversion factor to compare BNP and NT-proBNP levels. An NT-proBNP level &gt;900",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    provides roughly equivalent accuracy as a BNP level of &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    for diagnosis of heart failure.",
"   </p>",
"   <p>",
"    A study of 164 patients hospitalized with decompensated heart failure found that admission and discharge NT-pro-BNP and BNP levels predicted cardiac mortality and all-cause mortality at 90 day follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/75\">",
"     75",
"    </a>",
"    ]. NT-pro-BNP had greater prognostic value than BNP levels for all-cause mortality.",
"   </p>",
"   <p>",
"    As alluded to above, greater increases in NT-proBNP than BNP levels are observed in renal failure. (See",
"    <a class=\"local\" href=\"#H22200902\">",
"     'Renal failure'",
"    </a>",
"    above.) It has been postulated that the diagnostic value of NT-proBNP may be in part be due to its sensitivity to renal dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27657875\">",
"    <span class=\"h1\">",
"     BNP OR NT-proBNP AS GUIDE TO THERAPY OF HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma concentrations of BNP and NT-proBNP fall after effective chronic treatment of HF, which suggests that measurement of plasma BNP may be helpful in titrating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/45,50,76-79\">",
"     45,50,76-79",
"    </a>",
"    ]. The utility of serial BNP measurements to monitor the response to acute HF therapies is currently being investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27657882\">",
"    <span class=\"h2\">",
"     Chronic HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials studying the effect of BNP- or NT-proBNP guided therapy on clinical outcomes have shown mixed results, although the weight of the evidence suggests a mortality benefit. The data suggest that medical therapy can often be uptitrated and optimized even in the absence of worsening clinical symptoms, particularly in patients less than 75 years old.",
"   </p>",
"   <p>",
"    A meta-analysis of eight randomized",
"    <sup>",
"    </sup>",
"    trials with a total of 1726 patients with 16 months mean follow-up reported the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <sup>",
"      </sup>",
"      risk of all-cause mortality was significantly lower in the BNP-guided group compared with the control group (RR 0.76, 95% CI, 0.63-0.91).",
"     </li>",
"     <li>",
"      In the subgroup",
"      <sup>",
"      </sup>",
"      of patients younger than 75 years, all-cause mortality was also",
"      <sup>",
"      </sup>",
"      significantly lower in the BNP-guided group (RR 0.52, 95% CI",
"      <sup>",
"      </sup>",
"      0.33-0.82). However, there was no reduction",
"      <sup>",
"      </sup>",
"      in mortality with BNP-guided therapy in patients 75 years or older (RR 0.94, 95% CI 0.71-1.25). It is unclear whether the lack of improvement in patients aged 75 or older was due to differences in baseline characteristics (such as higher ejection fraction and more frequent hypertension) or other causes for differing responses to treatment.",
"     </li>",
"     <li>",
"      The",
"      <sup>",
"      </sup>",
"      risk of all-cause hospitalization (data from three trials) and survival free of any hospitalization (data from two trials)",
"      <sup>",
"      </sup>",
"      was not significantly different between the groups (RR 0.82, 95%",
"      <sup>",
"      </sup>",
"      CI 0.64-1.05 and RR 1.07, 95% CI 0.85-1.34, respectively).",
"     </li>",
"     <li>",
"      The percentage",
"      <sup>",
"      </sup>",
"      of patients achieving target doses of angiotensin-converting",
"      <sup>",
"      </sup>",
"      enzyme inhibitors and beta blockers during the course of these",
"      <sup>",
"      </sup>",
"      trials averaged 21 percent and 22 percent in the BNP group and 11.7 percent and 12.5 percent",
"      <sup>",
"      </sup>",
"      in the control group, respectively.",
"      <sup>",
"      </sup>",
"      This observation suggests that",
"      <sup>",
"      </sup>",
"      increased use of evidence-based agents may have contributed to the mortality benefit from BNP monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest trial in the meta-analysis was the TIME-CHF trial in which 499 patients aged &ge;60 years old with NYHA class II or greater HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and LVEF &le;45 percent were randomly assigned to symptom-guided therapy or NT-proBNP guided therapy (goal level less than twice the upper limit of normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uptitration of medical therapy was greater at each visit in the NT-proBNP guided group as compared to the symptom-guided group.",
"     </li>",
"     <li>",
"      The two treatment groups had similar rates of 18 month survival free of all-cause hospitalizations (41 and 40 percent) and similar improvements in quality of life. Survival free of hospitalization for HF, a secondary end-point, was higher among those in the NT-proBNP group (72 versus 62 percent).",
"     </li>",
"     <li>",
"      Heart failure therapy guided by NT-proBNP improved outcomes in patients aged 60 to 75 years but not in those aged 75 years or older.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials published subsequent to the meta-analysis have produced mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The above meta-analysis included initial data based on two-year follow-up from the BATTLESCARRED trial. A subsequent analysis at three years found that in patients &le; 75 years old, mortality was reduced by NT-proBNP guided therapy as compared to clinically managed treatment or usual care (15.5 versus 30.9 and 31.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/82\">",
"       82",
"      </a>",
"      ]. No significant benefit from NT-proBNP guided therapy was observed in patients &gt;75 years old.",
"     </li>",
"     <li>",
"      The UPSTEP trial (n=279) found no morbidity or mortality benefit from BNP-guided treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/83\">",
"       83",
"      </a>",
"      ]. However, patients with &gt;30 percent decline from baseline BNP levels had improved clinical outcomes.",
"     </li>",
"     <li>",
"      A trial randomly assigned 278 patients to NT-proBNP guided care, multidisciplinary care, or usual care [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/84\">",
"       84",
"      </a>",
"      ]. Mortality at one year was significantly lower in the guided care (22 percent) and multidisciplinary care (22 percent) groups compared to usual care group (39 percent). The NT-proBNP guided group had significant reduced days of HF hospitalization compared to the other two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The plasma BNP concentration may also predict the likelihood of response to therapeutic intervention. In the Australia-New Zealand Heart Failure study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    appeared to reduce mortality only in patients with supramedian baseline values of BNP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27657889\">",
"    <span class=\"h3\">",
"     Exercise training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise training programs are recommended in patients with chronic heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiac rehabilitation in patients with heart failure\", section on 'Effects of exercise in heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of exercise training on natriuretic peptide levels was evaluated in a series of 95 patients randomly assigned to either exercise training or standard therapy for nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/85\">",
"     85",
"    </a>",
"    ]. In addition to a number of clinical improvements, patients assigned to exercise training had a decline in both BNP and N-terminal pro-BNP of approximately 30 percent, compared to no change in patients assigned to standard therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27657896\">",
"    <span class=\"h2\">",
"     Acute HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the half-life of natriuretic peptides is relatively short (the half-life for BNP being shorter than that for NT-proBNP), serial measurements may be of value in guiding the management of acute, decompensated HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/86\">",
"     86",
"    </a>",
"    ]. However, short-term changes in BNP or NT-proBNP levels have been studied only in small series, with conflicting results. Also, some patients with acute HF do not have elevated BNP or NT proBNP levels if the etiology of the heart failure is inflow tract obstruction (eg, mitral stenosis), constrictive pericarditis, or if the heart failure is very acute (first hour or so). At present, the value of serial natriuretic peptide measurements in this setting has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27658361\">",
"    <span class=\"h3\">",
"     Measurement during treatment with nesiritide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is evaluating the hemodynamic response to therapy in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    (BNP 1-32). Plasma BNP should NOT be measured during the administration of nesiritide, since nesiritide will be detected as an acute increase in plasma BNP concentration (eg, from 700 to 13,000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. On the other hand, the NT-proBNP assay does not detect nesiritide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/89\">",
"     89",
"    </a>",
"    ]. A decline in NT-proBNP (but not BNP) levels was observed in a small series of patients treated with nesiritide and other HF therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/90\">",
"     90",
"    </a>",
"    ]. Thus, NT-proBNP assay may be helpful in assessing the response to therapy, although there are limited data to support this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=see_link\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     ATRIAL NATRIURETIC PEPTIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial natriuretic peptide (ANP) is primarily released from the atria in response to volume expansion, apparently sensed as atrial stretch. ANP levels are increased in HF and correlate more closely with atrial volume than atrial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/91\">",
"     91",
"    </a>",
"    ]. The prohormone of atrial natriuretic peptide (proANP) is a polypeptide of 126 amino acids. The N-terminal portion of proANP, termed proANP1&ndash;98 or NT-proANP, has a much longer half-life than mature ANP and has therefore been proposed as a more reliable analyte for measurement than ANP. An investigational commercial assay detects mid-regional pro-atrial natriuretic peptide (MR-proANP).",
"   </p>",
"   <p>",
"    The multicenter BACH (Biomarkers in Acute Congestive Heart Failure) trial evaluated the utility of monitoring MR-proANP as compared to BNP in 1641 patients presenting to the emergency department with shortness of breath [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/92\">",
"     92",
"    </a>",
"    ]. MR-proANP (&ge;120",
"    <span class=\"nowrap\">",
"     pmol/l)",
"    </span>",
"    was noninferior to BNP (&ge;100",
"    <span class=\"nowrap\">",
"     pg/ml)",
"    </span>",
"    for the diagnosis of AHF (sensitivity 97 versus 95.6 percent; specificity 59.9 versus 61.9 percent). MR-proANP provided additional discriminant value to BNP in patients with intermediate BNP (or NT-proBNP levels) or obesity but not in those with renal insufficiency, age &gt;70 y, or edema.",
"   </p>",
"   <p>",
"    The GISSI-HF trial provided evidence that measurement of MR-proANP provided prognostic information independent of NT-proBNP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/93\">",
"     93",
"    </a>",
"    ]. Natriuretic peptides and other vasoactive peptides were measured in 1237 patients with chronic stable HF at randomization and at three months. The addition of MR-proANP improved classification for mortality when added to models based on clinical risk factors alone (net reclassification improvement [NRI] = 0.12) or together with NT-proBNP (NRI =0.06). Increases in MRproANP levels were associated with mortality (HR 1.38, 95% CI 0.99&ndash;1.93 and HR 1.58, 95% CI 1.13&ndash;2.21 in the middle and highest versus lowest tertiles).",
"   </p>",
"   <p>",
"    More data are needed to define the clinical utility of MR-proANP measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1203669\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) concentrations vary with the assay used, age, sex, and body mass index. The normal values tend to increase with age and to be higher in women than men and lower in obese individuals. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Plasma BNP'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Plasma N-terminal pro-BNP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In normal subjects, the plasma concentrations of BNP and NT-proBNP are similar (approximately 10",
"      <span class=\"nowrap\">",
"       pmol/L).",
"      </span>",
"      However, in patients with LV dysfunction, plasma NT-proBNP rises more than BNP, with NT-proBNP concentrations approximately four-fold higher than BNP concentrations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Plasma N-terminal pro-BNP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with chronic kidney disease, decreased glomerular filtration rate (GFR) is associated with increased plasma BNP and even greater elevation in NT-proBNP concentrations, since NT-proBNP is cleared by the kidney. (See",
"      <a class=\"local\" href=\"#H22200902\">",
"       'Renal failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Variability in peptide measurements must be considered when interpreting serial BNP or NT-proBNP results. Intraindividual biologic variation as well as analytic assay variation contribute to total variation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Variability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma BNP or NT-proBNP is useful as a component of the evaluation of suspected heart failure (HF) when the diagnosis is uncertain. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'BNP and the diagnosis of HF in the patient with dyspnea'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H16#H16\">",
"       \"Evaluation of the patient with suspected heart failure\", section on 'BNP and NT-proBNP'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most dyspneic patients with HF have plasma BNP values above 400",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      while values below 100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      have a very high negative predictive value for HF as a cause of dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?19/22/19818/abstract/28\">",
"       28",
"      </a>",
"      ]. In the range between 100 and 400",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      plasma BNP concentrations are not very sensitive or specific for detecting or excluding HF. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Summary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients &lt;50, 50 to 75, and &gt;75 years of age, the optimal plasma NT-proBNP cutoffs for diagnosing HF were 450",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      900",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      and 1800",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      respectively. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Acute decompensated HF'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevations in plasma BNP can establish the presence of HF due to diastolic dysfunction with similar accuracy to systolic dysfunction. However, the values do not differentiate between systolic and diastolic dysfunction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diastolic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Not all patients with symptomatic HF have high plasma BNP or NT-proBNP concentrations and not all asymptomatic patients have low values. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Discordance between BNP and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials studying the effect of BNP- or NT-proBNP guided therapy on clinical outcomes have shown mixed results, although the weight of the evidence suggests a mortality benefit. (See",
"      <a class=\"local\" href=\"#H27657882\">",
"       'Chronic HF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The value of serial BNP measurement in guiding management of acute HF has not been established. (See",
"      <a class=\"local\" href=\"#H27657896\">",
"       'Acute HF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma BNP and NT-proBNP provide prognostic information in patients with acute and chronic HF, and plasma BNP has prognostic value in those with asymptomatic or minimally symptomatic LV dysfunction. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prognosis of HF'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mid-regional pro-atrial natriuretic peptide (MR-proANP) appears to be noninferior to BNP for diagnosis of acute HF and to have prognostic value in patients with chronic HF. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Atrial natriuretic peptide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Natriuretic peptide levels are elevated in some patients without clinical evidence of heart failure. The potential value of natriuretic peptide measurement in patients with coronary heart disease, valve disease, constrictive pericarditis, pulmonary hypertension, and sepsis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29573?source=see_link\">",
"       \"Natriuretic peptide measurement in non-heart failure settings\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/1\">",
"      Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/2\">",
"      Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/3\">",
"      Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001; 37:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/4\">",
"      Elsner D, M&uuml;ntze A, Kromer EP, Riegger GA. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992; 70:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/5\">",
"      Wilkins MR, Unwin RJ, Kenny AJ. Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993; 43:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/6\">",
"      Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/7\">",
"      Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/8\">",
"      Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000; 46:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/9\">",
"      Tjeerdsma G, de Boer RA, Boomsma F, et al. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2002; 86:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/10\">",
"      Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002; 144:834.",
"     </a>",
"    </li>",
"    <li>",
"     Product information available at www.biosite.com/products/triage.aspx (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/12\">",
"      Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003; 108:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/13\">",
"      Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/14\">",
"      Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/15\">",
"      Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/16\">",
"      Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/17\">",
"      Clerico A, Carlo Zucchelli G, Pilo A, et al. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/18\">",
"      Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006; 152:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/19\">",
"      Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/20\">",
"      McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/21\">",
"      Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 2005; 67:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/22\">",
"      Takami Y, Horio T, Iwashima Y, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/23\">",
"      Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006; 47:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/24\">",
"      Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/25\">",
"      Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/26\">",
"      McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004; 164:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/27\">",
"      Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006; 47:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/28\">",
"      Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation 2002; 105:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/29\">",
"      de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/30\">",
"      Mair J. Biochemistry of B-type natriuretic peptide--where are we now? Clin Chem Lab Med 2008; 46:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/31\">",
"      Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/32\">",
"      McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/33\">",
"      McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/34\">",
"      Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/35\">",
"      Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/36\">",
"      Knudsen CW, Omland T, Clopton P, et al. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004; 116:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/37\">",
"      Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 2004; 44:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/38\">",
"      Knudsen CW, Omland T, Clopton P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005; 46:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/39\">",
"      Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/40\">",
"      Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/41\">",
"      Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/42\">",
"      Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006; 166:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/43\">",
"      Schneider HG, Lam L, Lokuge A, et al. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med 2009; 150:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/44\">",
"      Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108:2964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/45\">",
"      Stanek B, Frey B, H&uuml;lsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/46\">",
"      Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/47\">",
"      de Groote P, Dagorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004; 43:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/48\">",
"      Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/49\">",
"      Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/50\">",
"      Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/51\">",
"      Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999; 99:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/52\">",
"      Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/53\">",
"      Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/54\">",
"      Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/55\">",
"      Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/56\">",
"      Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/57\">",
"      Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/58\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/59\">",
"      . Evaluation of patients for ventricular dysfunction and heart failure. J Card Fail 2006; 12:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/60\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/61\">",
"      Tsch&ouml;pe C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/62\">",
"      Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/63\">",
"      Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/64\">",
"      Bay&eacute;s-Gen&iacute;s A, Santal&oacute;-Bel M, Zapico-Mu&ntilde;iz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/65\">",
"      Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/66\">",
"      Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 2006; 27:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/67\">",
"      Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115:3103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/68\">",
"      Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/69\">",
"      Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/70\">",
"      Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/71\">",
"      Schou M, Gustafsson F, Corell P, et al. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J 2007; 154:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/72\">",
"      Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/73\">",
"      Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/74\">",
"      Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003; 21:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/75\">",
"      Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 2008; 51:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/76\">",
"      Yoshimura M, Mizuno Y, Nakayama M, et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 2002; 112:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/77\">",
"      Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/78\">",
"      Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/79\">",
"      Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/80\">",
"      Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med 2010; 170:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/81\">",
"      Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/82\">",
"      Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/83\">",
"      Karlstr&ouml;m P, Alehagen U, Boman K, et al. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 2011; 13:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/84\">",
"      Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010; 55:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/85\">",
"      Passino C, Severino S, Poletti R, et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 2006; 47:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/86\">",
"      Bhardwaj A, Januzzi JL Jr. Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. Crit Pathw Cardiol 2009; 8:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/87\">",
"      Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 2005; 96:32G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/88\">",
"      Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/89\">",
"      Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007; 49:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/90\">",
"      Miller WL, Burnett JC Jr, Hartman KA, et al. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. Clin Chim Acta 2009; 406:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/91\">",
"      Globits S, Frank H, Pacher B, et al. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure. Am Heart J 1998; 135:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/92\">",
"      Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/22/19818/abstract/93\">",
"      Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010; 12:338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3486 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19818=[""].join("\n");
var outline_f19_22_19818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1203669\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC ROLE IN HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSAY INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Plasma BNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Plasma N-terminal pro-BNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Assay purity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201902\">",
"      Impact of other conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22200902\">",
"      - Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27939917\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22201975\">",
"      - Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PLASMA BNP IN HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BNP and the diagnosis of HF in the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Breathing Not Properly study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Impact on outcomes and costs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Discordance between BNP and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prognosis of HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Chronic HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Acute decompensated HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Screening for LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Major society recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      N-TERMINAL PRO-BNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Role in HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Acute decompensated HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Primary care setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Role in cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      COMPARISON OF PLASMA BNP AND N-TERMINAL PRO-BNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27657875\">",
"      BNP OR NT-proBNP AS GUIDE TO THERAPY OF HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27657882\">",
"      Chronic HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27657889\">",
"      - Exercise training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27657896\">",
"      Acute HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27658361\">",
"      - Measurement during treatment with nesiritide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      ATRIAL NATRIURETIC PEPTIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1203669\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3486|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/13/20701\" title=\"figure 1\">",
"      ANP BNP LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/60/6094\" title=\"figure 2\">",
"      Mechanism ANP BNP HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/28/40397\" title=\"figure 3\">",
"      BNP levels etiology dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/56/36750\" title=\"figure 4\">",
"      BNP and survival ValHeFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/44/17101\" title=\"figure 5\">",
"      BNP and survival in HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29573?source=related_link\">",
"      Natriuretic peptide measurement in non-heart failure settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=related_link\">",
"      Nesiritide in the treatment of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=related_link\">",
"      Screening for asymptomatic left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_22_19819="72h fecal fat test";
var content_f19_22_19819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Seventy-two hour fecal fat collection and calculation of coefficient of fat absorption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. Forty-eight hours prior to the beginning of stool collection, subject is started on a high fat diet (&gt;2 gm/kg/day and minimum of 50 gm/day fat).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. All stools are collected into a single container for a full 72 hours.  Stool container is kept refrigerated during collection.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. During the collection, all food and fluid intake is recorded.  A record of all bowel movements is kept.  Intake record is analyzed for total dietary fat intake.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Collected stool is homogenized and analyzed for fat by the method of van de Kamer*.  Medium chain triglyceride will not be measured by this method.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Coefficient of fat absorption (CFA) is calculated from the following equation:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       <p>",
"        CFA = Dietary fat - Stool fat",
"       </p>",
"       <p>",
"        ------------------------",
"       </p>",
"       <p>",
"        Dietary fat",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This protocol is intended for clinical use. This protocol is not sufficiently precise to be used for research purposes.",
"    <div class=\"footnotes\">",
"     * Van de Kamer, JH, et al. Rapid method for the determination of fat in feces. J Biol Chem 1949; 177:347.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert D Baker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19819=[""].join("\n");
var outline_f19_22_19819=null;
var title_f19_22_19820="Helminths with marked eos";
var content_f19_22_19820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Helminthic parasitic diseases causing marked eosinophilia (&gt;3000/&micro;L)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parasite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiostrongyliasis costaricensis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascariasis",
"       </td>",
"       <td>",
"        Early transpulmonary larval migration, often absent",
"when mature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hookworm",
"infection",
"       </td>",
"       <td>",
"        Early transpulmonary larval migration, often mild when",
"mature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strongyloidiasis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichinosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visceral larva migrans",
"       </td>",
"       <td>",
"        Primarily in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gnathostomiasis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Filariases:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tropical pulmonary",
"eosinophilia",
"       </td>",
"       <td class=\"sublist_other\">",
"        Especially in expatriates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Loiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Onchocerciasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Flukes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Schistosomiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        During early infection in non-immunes (Katayama fever)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fascioliasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        During early infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clonorchiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        During early infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paragonimiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        During early infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fasciolopsiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        During early infection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Weller, PF. Med Clin North Am 1992; 76:1413.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19820=[""].join("\n");
var outline_f19_22_19820=null;
var title_f19_22_19821="Drugs and G6PD deficiency";
var content_f19_22_19821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PARTIAL list of drugs and chemicals thought to be safe or unsafe in individuals with glucose-6-phosphate dehydrogenase deficiency*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Unsafe for class I, II, and III variants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acetanilid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dapsone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Furazolidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methylene blue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nalidixic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Naphthalene (mothballs, henna)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Niridazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrofurantoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenazopyridine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylhydrazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primaquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfacetamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfamethoxazole",
"            <sup>",
"             &Delta;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfanilamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfapyridine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiazosulfone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toluidine blue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trinitrotoluene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Uricase (rasburicase, pegloticase)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Safe for class II and III variants",
"            <span class=\"small\">",
"             <sup>",
"              &bull;",
"             </sup>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acetaminophen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aminopyrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ascorbic acid (except in very high doses)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloramphenicol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloroquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colchicine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diphenhydramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            L-DOPA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Menadione",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraaminobenzoic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenacetin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Probenecid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyrimethamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfamethoxpyridazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfisoxazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethoprim",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tripelennamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin K",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Note: This is a partial listing only. See text for information on how to obtain a more comprehensive listing of safe and unsafe agents.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Safety for class I variants is usually not known.",
"      <br>",
"       &Delta; The relative safety of this medication for patients with class II and III variants is unclear. See text for details.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Beutler E. G6PD deficiency.&nbsp;Blood 1994; 84:3613.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19821=[""].join("\n");
var outline_f19_22_19821=null;
var title_f19_22_19822="Aldosterone and potassium";
var content_f19_22_19822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Role of aldosterone in potassium homeostasis via appropriate changes in urinary potassium excretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 234px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19822=[""].join("\n");
var outline_f19_22_19822=null;
var title_f19_22_19823="Gram stain sputum 9";
var content_f19_22_19823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain sputum 9",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_22_19823=[""].join("\n");
var outline_f19_22_19823=null;
